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Abstract 
 
Background: Increased oxidative stress, inflammatory responses and mitochondrial 
dysfunction have been implicated in diabetes, obesity (diabesity) and cardiovascular 
diseases. Type 2 diabetes is the most common metabolic disorder, characterized by 
insulin resistance and pancreatic islet β-cell failure. The most common complications 
associated with type 2 diabetes are hyperinsulinemia, hyperglycemia, 
hyperlipidemia/dyslipidemia, increased inflammatory and reduced insulin response. 
Aspirin (ASA) and other non-steroidal anti-inflammatory drugs (NSAIDs) have been 
associated with the prevention of diabetes, obesity and related cardiovascular 
disorders. Aspirin has been used in many clinical and experimental trials for the 
prevention of diabetes and associated complications.  Aims and hypothesis: Since 
inflammation, oxidative stress and mitochondrial dysfunction are hallmarks of many 
degenerative diseases, including diabetes, and aspirin and other NSAIDs have been 
used in clinical trials for the prevention of diabetes and related complications, we 
hypothesize that ASA might be involved in altering the molecular and metabolic 
targets affected in type 2 diabetes.  Thus our main aim was to elucidate the 
mechanism of aspirin action in the pathophysiology and progression of disease using 
an experimental rat model for type 2 diabetes.  Methods: In this study, five month 
old Goto-Kakizaki (GK) rats, which showed signs of hyperglycemia were used. Two 
subgroups of GK and Wistar control rats were injected intraperitoneally with 100 mg 
aspirin/kg/body weight/day for 5 weeks. Animals were sacrificed and blood and 
tissues were collected after performing glucose tolerance (2 h post 2g IP glucose 
ingestion) tests in experimental and control groups.  Results: Aspirin caused a 
decrease in hyperglycemia which was accompanied by a significant improvement in 
glucose tolerance after ASA treatment in GK rats compared to the nondiabetic 
Wistar rats. Also, the ASA treated GK rats exhibited a significant decrease in 
insulinemia. ASA treatment caused a marked reduction in the pro-inflammatory 
prostaglandin, PGE2, which was significantly higher in GK rats. Aspirin treatment 
also improved energy metabolism in peripheral tissues. On the other hand, no 
significant organ toxicity was observed after ASA treatment at this dose and time 
period. However, the total cholesterol and lipoprotein levels were significantly 
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increased in GK rats, which decreased after ASA treatment. Immunofluorescence 
staining for insulin/glucagon secreting pancreatic cells showed improved β-cell 
structural and functional integrity in ASA-treated rats which was also confirmed by 
SDS-PAGE and Western blot analysis.  Conclusion: The improved glucose tolerance 
in ASA-treated GK rats may be associated with increased insulin responses due to 
the anti-inflammatory properties of ASA and improvements in ROS/RNS –
dependent (oxidative stress related) alterations in mitochondrial functions which 
facilitated insulin signaling and energy utilization in target tissues. These results may 
have implications in determining the therapeutic use of ASA in insulin-resistant type 
2 diabetes.  Significance: Since the UAE is one of the fastest growing countries 
where type 2 diabetes is prevalent, our study could help in identifying the metabolic 
targets affected in diabetes and after treatment with aspirin. The study might be 
significant in designing therapeutic strategies and in the management of this chronic 
disease. 
 
Keywords: Type 2 diabetes mellitus (T2DM), insulin resistance, insulin signaling, 
metabolic alterations, aspirin (ASA), oxidative stress, energy metabolism. 
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 )cibarA ni( tcartsbA dna eltiT
 
 تأثيرات الأسبرين على التغيرات الاستقلابية في النوع الثاني لداء السكري
 الملخص
تسببت زيادة الاكسدة ، والاستجابات الالتهابية و ضعف الميتوكوندريا في مرض السكري ، والسممةة               
همو اضماراا التمليمل الئم الأي الأكلمر  2) و أمراض القلب والأوعيمة الدمويمةا السمكري  من الةمو   ytisebaid
جزيمرة فمي البةكريما ا المفماعاات الأكلمر شميوعا  شيوعا ، والتي تتميز بمقاو مة الأنسمولين و ف مل ا يما بيتما
و فرط، ارتاما  السمكر فمي المدل والمدهوض ر اضماراا شممول المدل ، وزيمادة  2المرتباة بداء السكري من الةو  
) وغيرهما  من العقما ير غيمر السمتيرويدية المفمادة  ASAالتهابات وانخاماض اسمتجابة الأنسمولين ا الاسمبرين   
ات ) ارتباممت  ممو الو ايممة  ممن  ممرض السممكري ، والسمممةة واضممارابات القلممب والأوعيممة ل لتهابممات   المسممكة
الدمويمة تات الةملةا و مد اسمتخدل الاسمبرين فمي العديمد ممن التجمارا السمريرية والتجريبيمة للو ايمة ممن ممرض 
 السكري والمفاعاات المةاحبة
كونمدريا همي السممات المميمزة   الأهداف و الارضية: مة  الالتهاا والإجهاد التأكسدي و ضعف الميتو
كلير من الأمراض التةكسية ، بما في تلك مرض السكري ، والأسمبرين و مفمادات الالتهماا غيمر السمتيرولأيدية 
الأارى التمي اسمتخدمت فمي التجمارا السمريرية للو ايمة  من  مرض السمكري و مفماعااتف ، ون من ناتمرض أض 
ا  2التمليمل الئم الأي تتمأفر فمي  مرض السمكري  من الةمو   د يكموض متورطما فمي تئييمر أهمداف جزي يمة و  ASA
وهك ا كاض هدفةا الرلأيسي لتوضمي  لليمة ع مل الأسمبرين فمي الايزيولوجيما المرضمية و تامور ال مرض باسمتخدال 
 2نموتج الا راض التجريبية لمرض السكري من الةو  
، والتي أظهرت ع مات على  )KG(في ه ه الدراسة، تم استخدال الا راض عمر امسة أشهر الطريقة:
ملم/ ر ديسميلتر ف مراض  06-55ملم/ ر ديسميلتر مقابمل  59-08ارتاما  السمكر فمي المدل  الجلوكموز دمالأم فمي المدل 
ملم/ الأسمبرين  001البريتونى  مو  سليمفوجرتاض ويستار  KG)ا تم حقن مجموعتين فرعيتين من سليمفويستار 
الممدل والأنسممجة بعممد اداء تم ممل  ج ممو .بالميوانمماتأسممابيوا ت ممت التفمممية  5ل ممدة  ,ر كمم/ ر وزض الجسممم ر يممول
 الجلوكوز الابت  ) ااتبارات في المجموعتين الفاباة والتجريبيةا PI G2 ساعة بعد حقن 2الئلوكوز  
: تسبب الأسبرين انخااض في ارتاا  السمكر فمي المدل والم ي كماض يرافقمف تمسمن كبيمر فمي تم مل النتائج          
بالمقارنة مو الا راض ويستار غير مةابين بالسكرا أيفا، أظهمرت  KGفي الا راض  ASAالئلوكوز بعد الع ج 
نخاماض مل موظ فمي ا ASAتعامل انخااضا كبيرا في الأنسمولين فمي المدلا تسمببت المعاملمة  ASA KGالا راض 
ا تمسمن دواء KG، الم ي كماض أعلمى ب مكل مل موظ فمي الا مراض 2EGPالبروسمتاج ندين المواليمة ل لتهابمات، 
الأسبرين أيفا استق ا الاا ة في الأنسجة الارفيةا  من ناحيمة أامرى، لمم ي حمس أي سممية الجهماز كبيمرة بعمد 
فقمد ارتامو مج مالي الكولسمترو  والبمروتين المدهةي  فمي هم ه الجرعمة والاتمرة الزمةيمةا وممو تلمك، ASAالعم ج 
ا أظهر المةماعي تلاميل لسنسمولين ASA، والتي انخافت بعد الع ج KGالمستويات ب كل ملموظ في الا راض 
 x
 
ر الجلوكمماجوض مفممراز ا يمما البةكريمما وتمسممين ا يمما بيتمما السمم مة الهيكليممة والوظيايممة فممي الا ممراض المعالجممة 
 وتمليل لاخة غربيةا EGAP-SDSأيفا وهو ما أكده -ASA
 مد تترافمم  مو زيمادة اسمتجابات الأنسمولين -ASAتعا مل  KGتمسمن سمكر المدل فمي الا مراض  الخلاصة:          
معت ممد علممى  الاكسممدة تات  SNR / SORوالتمسمميةات فممي  ASAنظمرا لخةممالأا مفممادة ل لتهابممات ممن 
ت مشممارات الأنسممولين و اسممتخدال الاا ممة فممي الأنسممجة الةمملة) تئيممرات فممي وظممالأف الميتوكونممدريا التممي سممهل
فممي  ممرض السممكري مقاو ممة  ASAالمسممتهدفةا  ممد يكمموض لهمم ه الةتممالأت لفممار فممي تمديممد الاسممتخدال الع جممي لممل
 ا2لسنسولين من الةو  
ي ، من  مرض السمكر 2الإمارات العربية المتمدة هي واحدة من أسر  البلداض نموا فمي نمو   الاهمية:           
التي تتأفر بمرض السكري وبعد الع ج مو الأسبرينا  د تكوض  يمكن أض تساعد دراستةا في تمديد اهداف الأيض
 ه ه الدراسة هامة في تةميم الاستراتيجيات الع جية وفي مدارة ه ا المرض المزمنا
،  الأنسمولين مشمارات مقاوممة الأنسمولين ،) ،  MD2T   2داء السمكري ممن الةمو   :مفااهيا الب ار الرئيساية
 ) ، الاكسدة ، والتمليل الئ الأي للاا ة ا ASAالأسبرين   تعدي ت التمليل الئ الأي ، 
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Chapter 1: Introduction 
 
1.1 Overview 
Diabetes mellitus (DM), the most widespread complex metabolic disorder 
among the world‘s population, is affecting millions of people globally.  The 
prevalence is increasing rapidly. A recent study by Guariguata et al. representing 130 
countries reported in 2013 that 382 million people were diabetic and this number was 
expected to rise to 592 million by 2035 (1).  Furthermore, there were a number of 
undiagnosed cases of diabetes mellitus and impaired glucose tolerance, which could 
further increase leading to higher numbers of people suffering from diabetes-
associated vascular and metabolic complications (2). Similarly, the prevalence of 
diagnosed and undiagnosed diabetes, generally associated with obesity, is increasing 
in the Middle-East region. Almost one in 20 people suffer from diabetes in the 
United Arab Emirates and this number is among the highest worldwide (3). 
 
Apart from hyperglycemia, dyslipidemia and glycosylated hemoglobin 
(Hb1ac), there are a number of biomarkers being used to elucidate the chronic 
complications of diabetes.  The main pathophysiological complications of diabetes 
are considered to be associated with hyperglycemia, hyperlipidemia, and insulin 
resistance and may include cardiomyopathy, retinopathy, nephropathy, urinary tract 
infections and other metabolic complications (4). 
 
The diagnosis and classification of diabetes has evolved over time and has 
been revised due to challenges in the etiological, diagnostic and pathophysiological 
complications (5).  The classification system of type 1, type 2 are mainly based on 
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etiological factors still presents challenges due to the presence of additional causative 
factors, therefore a number of subgroups under the different types of diabetes have 
also been suggested (5-7).  
American Diabetes Association has come up with a new classification system 
for diabetes based on a β-cell-centric classification scheme that excludes inherent and 
unnecessary confusion (8).  Although still popular as type 1 (previously, insulin-
dependent diabetes mellitus) or type 2 (insulin-independent diabetes mellitus) there 
is an urgent need to review the current classification system towards the consensus 
on a more useful and unified system. 
1.2 Type 1 diabetes 
Type 1 diabetes (T1DM) accounts for 5–10% of the diabetic population.  It 
results from a cellular mediated autoimmune destruction of the β-cells of the 
pancreas that leads to absolute insulin deficiency. The pathogenesis of T1DM is 
known to include recruitment of CD4+ helper and CD8+ killer T lymphocytes and 
infiltration of macrophages, which lead to inflammatory cytokine-dependent islet 
destruction. 
(9).  Antibodies against insulin secreting cells, including those against insulin, 
glutamic acid decarboxylase (GAD) and against the whole islet cell involved in the 
development of T1DM can be detected at birth or in infancy (10).  Markers of this 
immune destruction of the cell include islet cell autoantibodies, autoantibodies to 
insulin, autoantibodies to glutamic acid decarboxylase (GAD65), and autoantibodies 
to tyrosine phosphatase IA2.  These autoantibodies are present in 85-90 % of the 
patients.  The disease seems to rapidly progress in infants and children, whereas in 
adults, it takes a longer time to progress (11). Children who are overweight (higher 
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BMI) are more prone to develop the disease (12-14).  T1DM is characterized by total 
insulin absence, or very low insulin levels resulting in hyperglycemia and 
ketoacidosis (15). 
The symptoms generally associated with the disease include frequent 
urination (polyuria) due to the osmotic effect of excess glucose in the urine, drinking 
plenty of water (polydipsia), muscle cramps due to electrolyte disturbance, blurred 
vision and weight loss.  Excessive fluid loss leads to dehydration (16).  
 
1.3 Type 2 diabetes 
Until a few years ago type 2 diabetes (non-insulin dependent) was considered 
a less complicated type of disease.  This idea has changed since type 2 diabetes 
mellitus (T2DM) shortened life expectancy of patients; and is also a leading cause of 
premature death due to its complications which include cardiovascular disease, 
blindness, amputations, and renal insufficiency.  The major causes of T2DMM and 
the most understood are insufficient β-cells response to insulin resistance and 
decrease in its peripheral action.  Genetic and environmental factors are the major 
causes of T2DM. 
The prevalence of T2DM has been increasing steadily all over the world.  As 
a result of this trend, it has become an epidemic in some countries due to the 
increased number of people affected.  T2DM increases with ageing, population, 
smoking, and high calorie diet intake, thereby adding to the already existing burden 
for healthcare providers, especially in under developed countries (1, 3, 17). 
 
Pollution and high levels of environmental toxins are also related to the 
development of T2DM.  Recently, some studies found a weak but positive  
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association of bisphenol (found in some plastic types) concentration in the urine and 
T2DM (18). 
Type Characteristic  
Clinical comment 
 
Type 1 Autoimmune, previously called 
juvenile or insulin-dependent diabetes 
mellitus 
Potential association with 
other autoimmune diseases 
Type 2 Polygenic and affected by environment Increasing incidence 
associated with higher 
life span and western 
cultural habits 
Gestational Rapid  clinical 
Progress 
Can continue after 
pregnancy 
Secondary Side effect of medications 
or pancreas dysfunction (e.g: steroids, 
and alcoholism) 
Causative disease or 
medication may also 
influence ocular and 
lacrimal function 
Genetic Genetic defects in insulin secretion or 
action 
Potential ocular 
associated 
malformations 
 
Table 1: Classification and observations on types of diabetes mellitus (19)  
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According to the International Diabetes Federation (IDF) statistics, it was 
estimated that 366 million people were diabetic in 2011; this number increased to 
387 million in 2014.  DM led to almost 4.6 million deaths in 2011 (20).  Estimates by 
the IDF indicate that the number of diabetics is expected to rise and reach up 592 
million by 2035 (1).  The prevalence of diabetes is increasing in the general 
population every year.  This increase is attributed mainly to sedentary life style, 
increased intake of high calorie diet, central obesity (large abdomen), and a high 
body mass index (BMI: weight (kg)/height (m)
2
). Almost 80% of people with DM 
live in low- and middle-income countries (21).  The incidence of T2DM varies 
noticeably from one geographical region to another, as a result of environmental and 
lifestyle risk factors.  Though prevalence of T2DM in Africa has been low, studies 
have shown a drastic increase in prevalence in both rural and urban areas, and 
affecting both gender similarly (20). 
In the last few years, there has been a drastic rise in T2DM among all age 
groups.  The UAE has been a member of the IDF since 2000; it comes under the 
Middle East and North Africa (MENA) region.  The MENA region has the second 
highest prevalence (9.7%) of diabetes in the regions (figure 1). The UAE has the one 
of the largest number of diabetics in the world; around 19% of the UAE population is 
diabetic (22).  There were 803,900 cases of diabetes in UAE in 2014. These numbers 
are expected to increase each year (20). 
These figures indicate that the region has high risk factors for diabetes, mainly due to 
the rising levels of obesity and physical inactivity. 
Sedentary lifestyle and increased consumption of unhealthy diet are the main 
contributors to the increased levels of obesity in the UAE.  High-risk people need to 
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Figure  1 : International Diabetes Federation; world regional diabetes classification.  
(21) 
be alert about their physical activities and diet.  This can decrease the chances of 
developing more complications.  Better understanding of the early symptoms of 
diabetes help people to be prepared to manage the disease and its complications (20).  
 
1.4 Metabolic changes in Type 1 diabetes  
T1DM is considered a more simple type of diabetes when compared to 
T2DM.  Despite high blood glucose levels, the cells seem to lack glucose as its 
uptake is insufficient due to insulin deficiency.  As a result, the liver keeps 
synthesizing glucose (gluconeogenesis) and ketone bodies (ketogenesis).  High 
glucagon levels have adverse action in DM.  The increased glucagon/ insulin ratio 
lead to decreased levels of fructose 2,6 bisphosphate that is vital for activating 
glycolysis and inhibiting gluconeogenesis.  Failure of glycolysis and excessive 
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gluconeogenesis exacerbate hyperglycemia.  Glucose is secreted in the urine 
accompanied by water; this explains the thirst and excessive urination in acute 
diabetes (23). 
Insulin deficiency affects other hormonal secretions such as decreased leptin 
from the adipose tissue and increased glucagon secretion.  Recent studies have 
shown that leptin deficiency in diabetic rats lead to increased pituitary gland 
production of adenocorticotropin hormone (ACTH).  This hormone stimulates the 
production of corticosterone from the adrenal gland, leading to increased lipolysis 
and production of free fatty acids (FFA) and glycerol from triglycerides. The FFA 
and glycerol produced reach the liver via the blood and get converted to glucose and 
ketone bodies.  This leads to hyperglycemia and ketoacidosis (15).  Β oxidation 
produces acetyl CoA which in this case is unable to enter the TCA cycle due to 
insufficient oxaloacetate (from pyruvate as an end-product of glycolysis).  The 
energy supply is changed to fat instead of carbohydrates. The high concentration of 
ketone bodies affects the kidneys’ ability to maintain the acid-base balance. 
Uncontrolled diabetes can lead to coma due to low blood pH levels and 
dehydration.  Ketosis is not seen in T2DM, as the insulin is sufficiently active to 
prevent lipolysis in the liver and adipose tissue (23). 
1.5 Metabolic changes in Type 2 diabetes 
T2DM is the most common endocrine metabolic disorder and is characterized 
by insulin resistance and pancreatic islet β-cell failure. Obesity, inflammation, 
oxidative stress, mitochondrial dysfunction have been implicated as etiological and 
pathophysiological risk factors for T2DM. Cardiomyopathy and other cardiovascular 
complications associated with increased inflammatory and oxidative stress responses 
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are the major causes of accelerated atherosclerosis in obesity and diabetes.  Insulin 
resistance is an early feature in T2DM development (24-27).  
Obesity is considered as one of the main reasons for developing insulin 
resistance in T2DM.  Inappropriate diet-related obesity and visceral adiposity are the 
main risk factors for the development of T2DM.  Many studies have shown that 
nutrient-induced β-cell dysfunction could be related to indirect initiation of low grade 
inflammation (28).  Hypertriacylglyceridemia and hypercholesterolemia due to 
increased circulating lipoproteins, may lead to high levels of triglycerides in blood 
and tissues that exceed the storage capability of adipocytes, leading to fat deposition 
in the organs.  The liver and muscles are the main sites for fat deposition.  Fat 
accumulation leads to the development of insulin resistance.  The rate of fatty acid β-
oxidation increases in response to high fat concentration.  The mitochondria reach a 
limit where they are unable to process the extra fatty acids by β-oxidation.  
Consequently, fat is deposited in the cytoplasm and is accompanied by increased 
levels of diacylglycerol and ceramide.  Diacylglycerol activates protein kinase C 
which regulates insulin receptor substrate (IRS) mediated insulin signaling leading to 
reduced insulin sensitivity.  Ceramide inhibits glucose uptake and glycogen synthesis 
(23). 
In T2DM, mitochondrial dysfunction in the tissues, particularly in the pancreas, 
due to proinflammatory responses and disturbance in redox homeostasis signaling 
have also been reported which may lead to increased oxidative stress (26).  Studies 
have also suggested that prolonged exposure to insulin, as seen in resistant T2DM 
suppresses mitochondrial biogenesis and function and this may lead to impairment of 
insulin sensitivity (29-30). 
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In chronic uncontrolled T2DM, insulin resistance induces stress on the β-cells in 
the pancreas to produce more proinsulin.  Proinsulin is stored in the ER, and 
excessive amounts can cause ER stress.  The ER stress lead to a signal induction that 
eventually protects the cell from damage.  It removes the extra proteins, and inhibits 
general protein synthesis.  If this fails to relieve the ER stress, apoptosis is activated 
leading to β cell death (23). 
1.6 Insulin structure 
Insulin was discovered in 1921 by Banting and Best (31).  It is a small protein 
with a molecular weight of 6000 Daltons.  It is made from two chains bound together 
by disulfide bonds.  Insulin's amino acids are highly conserved in vertebrates; 
structurally same insulin is active in different mammals.  Most insulin used to treat 
diabetics is extracted from pig’s pancreas (32). 
1.6.1 Biosynthesis of insulin 
Insulin is synthesized in large quantities in the β-cells of the pancreas.  Insulin 
mRNA is first translated as preproinsulin which is a single chain insulin precursor, 
which is then converted to proinsulin when the peptide group is removed after being 
moved to the ER (Figure 2). 
Proinsulin is made of three parts: an amino terminal A that consists of 21 amino 
acids, a carboxy terminal B chain which consists of 30 amino acids, and a C-peptide 
in the middle.  In the ER, many specific endopeptidases cut off the C peptide to form 
the mature form of insulin leaving the A chain and B chain connected together with a 
disulphide bond between A
7
- B
7
 and A
20
- B
19
.  Mature insulin and free C peptide are 
packaged in the Golgi and stored in secretory granules in the cytoplasm (33). 
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Figure 2: Insulin synthesis (183) 
Insulin production is stimulated by high blood glucose level, some neural 
stimuli, and high levels of fatty amino acids.  Glucose metabolism is needed for 
insulin release to be stimulated, this activates a sequence of events including 
generation of ATP, closure of K+ channels in the β-cell membrane and increased 
Ca
2+
 entry into the cell.  Subsequently, the β-cells excrete insulin by exocytosis and it 
diffuses in to the blood (34).  C peptides are also secreted, but their functions are not 
known.  Insulin released into the blood circulation is recognized by insulin receptors 
in target cells. 
 
1.7 Insulin receptor and cell signaling 
Insulin receptors (IR) are heterotetrameric glycoproteins on the cell surface.  
They consist of two α extracellular subunits that attach to insulin, and two β subunits 
that have tyrosine kinase specific protein activity, with a disulphide bond to link 
them. When an insulin molecule attaches to the receptor extracellularly, the tyrosine 
kinase is activated leading to the receptor's autophosphorylation and other 
intracellular proteins as well (insulin substrates -1, -2, -3, and -4).  Multiple 
downstream signaling pathways are activated after the phosphorylation (Figure 3). 
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The insulin receptor has different proximal substrates.  These include IRS-1, 
IRS-2, IRS-3, IRS-4. IRS-1 and IRS-2 are the most expressed substrates, whereas 
IRS-4 is only expressed in the brain, kidney and thymus. IRS-3 is expressed in the 
adipose tissue of rodents (35). 
The insulin signaling pathway starts when an insulin molecule binds to the 
insulin receptor (IR) activating tyrosine kinase activity (Figure 3).  The activated IR 
phosphorylates and recruits different substrates such as IRS-1 and IRS-2. The 
tyrosine phosphorylated IRS then provides binding sites for many signaling 
molecules. Among them, PI3K has a vital role in insulin function, mainly by the 
activation of the Akt/PKB and the PKCζ cascades. Activated Akt then activates 
glycogen synthesis through inhibition of GSK-3; protein synthesis through mTOR 
and downstream elements; and cell survival through inhibition of many pro-apoptotic 
agents, such as (Bad, FoxO transcription factors, GSK-3, and MST1). Akt 
phosphorylates and inhibits FoxO transcription factors that control metabolism and 
autophagy. AMPK also directly regulates FoxO3 and activates transcriptional 
activity. Insulin signaling plays a vital role in growth and mitogenic effects that are 
mediated by the Akt cascade as well as by activation of the Ras/MAPK pathway.  
Insulin stimulates glucose uptake in muscles and adipocytes through the 
translocation of GLUT4 vesicles to the plasma membrane.  Furthermore, insulin 
signaling prevents gluconeogenesis in the liver, by interfering with 
CREB/CBP/mTORC2 binding. Insulin signaling activates fatty acid and cholesterol 
synthesis by regulating SREBP transcription factors (36).  
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Hyperinsulinemia is a major characteristic of the metabolic syndrome.  It is 
the over production of insulin from pancreatic β-cells, and is considered a primary 
contributor to T2DM development and cardiovascular dysfunction (37).  
Understanding the mechanisms of insulin action and resistance is a vital step 
in the management of metabolic syndrome as well as development of therapeutic 
interventions to prevent or treat T2DM. 
1.8 Insulin and glucagon hormonal responses in diabetes 
Insulin and glucagon are considered the most important two hormones in 
diabetes.  Insulin is released in case of elevated blood glucose levels to stimulate 
glucose uptake by the liver and muscle to lower circulating glucose level.  Glucagon 
is secreted in case of decreased blood glucose levels, it increases glucose production 
from the liver to maintain normal blood glucose levels.  Most studies focus on 
insulin, whereas glucagon has been interpreted as a consequence, rather than a cause 
of diabetes.  But several studies have concluded that there is an association between 
elevated glucagon secretion and T2DM.  
Figure 3: Insulin Receptor stimulation. (182) 
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Weiping Han and co-workers at the A*STAR Singapore Bioimaging 
Consortium concluded from a study done in 2010 that dysregulated glucagon 
secretion, or lack of glucagon secretion inhibition with high blood glucose levels, can 
be a reason to develop T2DM. The study design included a high-fat diet given to 
normal mice and to genetically modified ‘knockout’ mice with impaired glucose 
tolerance, low insulin secretion and very less glucagon secretion. High-fat diet is 
known to reduce insulin sensitivity in mice. It was predicted that the knockout mice 
(known to have impaired insulin secretion) will develop T2DM sooner than the 
control mice.  Surprisingly, the control mice developed high glucose levels, whereas 
the knockout mice did not. This finding is evidence that reduced insulin secretion 
and sensitivity may not be the only factors to the development of T2DM, but also 
dysregulated glucagon secretion. That is why diabetes should be considered as a bi-
hormonal disease and more studies should focus on glucagon regulation (38-39). 
1.9 Insulin resistance in diabetes 
One of the main characteristics of T2DM is insulin resistance, when cells are 
unresponsive to insulin signaling.  In the late stages of insulin resistance, the 
pancreatic β cells fail to produce sufficient amounts of insulin.  Which eventually 
affects insulin signaling.  Skeletal muscles play an important role in insulin 
resistance, being the major organ for glucose storage obtained from food (40).  
Alterations in lipid metabolism and mitochondrial dysfunction in skeletal muscle 
have been connected to the etiology of T2DM but the underlying relationships with 
insulin resistance development remain to be clarified (41-42).  Increased levels of 
lipid oxidation are seen in the early stages of insulin resistance; however increased 
plasma levels of non-esterified fatty acids (NEFA) inhibit glucose uptake and 
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glycogen synthesis in skeletal muscles (43).  Additionally, it has been found that 
there is an increase in intramyocellular lipids (IMCL) (44). 
Insulin resistance, also known as insulin resistance syndrome is a major 
causative factor of metabolic syndrome.  There has been an alarming increase in 
metabolic syndrome. The main reasons for this syndrome are obesity, 
hyperglycemia, hyperlipidemia, and hypertension.  Various animal studies have 
demonstrated the role of insulin and its signaling cascade in controlling cell growth, 
metabolism and survival through the activation of mitogen activated protein kinase 
(MAPKs) and phosphotidylinositide 3 kinase (PI3K).  PI3K activation is associated 
with insulin receptor substrate 1, 2 (IRS1, 2) and eventually Akt and FOXO 1 
phoshporylation.  This cascade plays a vital role in nutrient homeostasis control and 
organ survival.  Hyperinsulinemia, metabolic inflammation, and over nutrition lead 
to inactivation of Akt and activation of FOXO 1, by suppressing IRS1, 2 in different 
organs leading to metabolic syndrome.  A good therapeutic intervention for diabetes 
and its complications could be through targeting IRS, Akt, FOXO 1 signaling 
cascade (4). 
Patients with T1DM suffer from insulin deficiency due to failure of 
pancreatic β-cells to produce insulin. The therapeutic intervention is insulin 
supplement to control hyperglycemia.  The scenario is different in T2DM, where 
pancreatic β-cells are producing sufficient insulin, which is not utilized properly.  
T2DM is non-insulin dependent, although insulin therapy can help reduce the 
hyperglycemia, but weight gain and cardiovascular risks are exacerbated.  
 
 
 
 
 
Figure 9:  Effect of aspirin treatment on tissue toxicity in control Wistar (C) and GK rats. 
Serum separated from the blood of the rats was subjected to analysis for total protein (A), 
uric acid (B), Alanine aminotransferase (ALT) (C), Aspartate aminotransferase (AST) 
(D), Lactate dehydrogenase (LDH) (E) and Creatine kinase (CK)  (F) on the COBAS® 
INTEGRA 400 plus auto-analyzer. Results are expressed as mean + S.E.M. from three 
independent experiments. 
15 
 
Insulin sensitivity (black line), acute insulin response (AIR, blue line), and blood 
glucose (red line). Impaired insulin sensitivity arises before evident changes in 
glucose; the insensitivity is compensated by an increased insulin secretion (AIR) 
during normoglycemia (blue shading). However, overtime AIR declines leading to 
impaired fasting glucose (gray shading) and development of T2DM (45). 
 
1.10 Chronic metabolic complications of diabetes  
As mentioned above, diabetic complications which arise due to insulin 
insufficiency (type 1) or insulin resistance (type 2) may develop into metabolic stress 
associated with energy metabolism, mitochondrial dysfunction and oxidative stress. 
These alterations may further complicate the pathophysiology of disease due to 
progressive accumulation of advanced glycation end products (AGE) leading to 
neuropathic, nephropathic and retinopathic symptoms complications. Some of these 
metabolic etiological and pathophysiological factors are discussed below. 
1.10. 1 Oxidative stress in diabetes 
Many experiments and clinical trials have shown that oxidative stress has a 
major role in the development of diabetes mellitus.  Excessive reactive oxygen 
Figure 4: Hypothesized time course of T2DM progression. 
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species (ROS) are produced in diabetes.  There are different cellular sources of ROS 
generation: peroxisomes, plasma membrane proteins, such as NADPH oxidase 
(NOX), cytosolic enzymatic reactions, and mitochondria.  Mitochondria produce 
around 90% of total cellular ROS (46).  Around 1% to 5% of the mitochondrial 
oxygen consumption is converted into superoxide anions and other ROS (47).  
Mitochondrial dysfunction leads to increased ROS production, increasing the 
potential for chromosomal abnormalities (48).  Increased ROS production has been 
implicated in abnormal glucose oxidation, non-enzymatic glycation of proteins, and 
oxidative degradation of glycated proteins.  High levels of ROS production and low 
levels of cellular anti-oxidant defense may damage cellular organelles and enzymes; 
it also increases lipid peroxidation leading to insulin resistance. The most important 
and first ROS generated by either mitochondria or by NOX is superoxide (O
2-.
). 
Superoxide anion radicals get dismutated by superoxide dismutase (SOD) to 
hydrogen peroxide (H2O2), which is eventually degraded under normal conditions by 
catalase or glutathione peroxidase enzyme systems.  Excess H2O2 which is not 
metabolized by these antioxidant enzymes may also be non-enzymatically 
metabolized by Fe
2+
 or other divalent ions to produce hydroxyl radicals.  Superoxide 
anions react with nitric oxide producing reactive peroxy-nitrite radicals (ONOO-).   
Hyperglycemia, as seen in diabetes, increases lipid peroxidation of low 
density lipoprotein (LDL) using a superoxide dependent pathway producing free 
radicals.  Hyperglycemia increases the levels of glucose that interact with proteins, 
producing Amadori products followed by advanced glycation end products (AGEs).  
The AGEs receptors (RAGEs) inactivate some enzymes by altering their structures 
leading to malfunctioning.   RAGEs also promote free radical formation, and inhibit 
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the anti-proliferative effects of nitric oxide.  As AGEs increase oxidative stress, they 
promote the up-regulation of various NF-kβ target genes.  NF-kβ increases nitric 
oxide production, which is an islet β cell damage mediator (49-50). 
Glucose plays a major role in activating the sorbitol (polyol) pathway that 
leads to diabetes complications, such as eye lens cataract and neuropathy.  Increased 
sorbitol dehydrogenase activity is closely related to altered NAD+ levels that lead to 
protein modification by non-enzymatic glycosylation of lens protein.  However, the 
mechanisms are still not fully understood (51-52). 
1.10.2 Redox homeostasis in diabetes 
Coupled oxidation reduction (redox) reactions, are vital to survival.  ROS are 
by-products of metabolism.  Natural antioxidants include vitamins (A, C, and E), 
glutathione, and enzymatic antioxidants such as superoxide dismutase, catalase, 
glutathione peroxidase and glutathione reductase (53).  They work in harmony 
remove ROS and control its adverse effects in the body.  There are countable 
evidence for increased levels of oxidative stress in T2DM.  The expression of 
antioxidants (SOD1, SOD 2, and catalases) in pancreatic β-cells is low compared to 
other tissues.  Chronic diabetes decreases the γ-glutamylcysteine ligase, the rate 
limiting enzyme for glutathione synthesis.  T2DM is associated with elevated 
markers of chronic oxidative stress, as β cells maintain a low level of antioxidant 
gene expression with a high level of glucose to inhibit the rate limiting enzyme for 
glutathione (54).  Prolonged hyperglycemia and hyperlipidemia are considered the 
main causes of increased oxidative stress, mitochondrial dysfunction, and fibrosis 
with diabetes complications. 
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 1.10.3 Mitochondrial dysfunction 
Cellular energy is produced by the mitochondria through inner membrane 
bound respiratory chain electron transport enzymes and oxidative phosphorylation 
(OXPHOS) of ADP. It also produces (ROS).  The mitochondrion is the main 
organelle controlling programmed cell death which is caused by energetic deficiency 
and ROS damage associated oxidative stress.  Most of the cellular ROS (O2
-
, H2O2 
and OH
.
) are toxic byproducts of mitochondrial OXPHOS. Increased ROS 
production due to abnormal oxygen metabolism in diabetes may result in reduced 
bioenergetics and mitochondrial dysfunction which ultimately may lead to insulin 
resistance and other complications of cell survival and death (apoptosis/mitophagy).  
The mitochondrial inner membrane respiratory complex enzymes include five 
multipolypeptide enzyme complexes.  Complexes I, II, III and IV make up the 
electron transport chain (ETC) and Complex V is adenosine triphoshpate (ATP) 
synthase. 
Metabolism of carbohydrates and fats generate NADH and FADH2 which 
donate electrons to the ETC. Complex I oxidizes the NADH
+
 (NADH: ubiquinone 
oxidoreductase, or NADH dehydrogenase).  Electrons are transported to ubiquinine 
(CoQ10) that gets reduced to ubisemiquinone (CoQ10H).  Electrons are then 
transported to Complex II from succinate (succinate oxidoreductase, succinate 
dehydrogenase (SDH)) that reduces CoQ10 to CoQ10H.  The electrons are then ferried 
to Complex III (ubiquinol: ferrocytochrome c oxidoreductase) to move them to 
cytochrome c.  Electrons are then passed on to complex IV (ferrocytochrome c: 
oxygen oxidoreductase), resulting in the formation of H2O (Figure 5).  The energy 
produced is used for proton pumping from the mitochondrial matrix through the 
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mitochondrial inner membrane, to the intermembrane space via complexes I, III, and 
IV. 
Abnormal mitochondrial respiratory complexes structure and /or function 
may lead to the leakage of electrons from ETC. Single electron reduction of oxygen 
in the mitochondria may produce ROS.  Increased ROS production may further 
increase oxidative modification and inhibition of respiratory complexes which might 
trigger the production of more ROS, i.e. ROS-induced ROS production. Some of the 
consequences of dysfunctional respiration have been studied.  A point mutation in 
the mitochondrial DNA (mtDNA) gene MTATP6 reduces mitochondrial respiratory 
activity and helps cancer promotion by inhibiting apoptosis (55) (56).  Growing 
evidence suggests that mitochondrial dysfunction due to oxidative damage is a major 
cause of aging, degenerative diseases like cancer, and metabolic syndrome, such as 
obesity and T2DM (42, 56).  
Insulin resistance in skeletal muscle plays a vital role in the pathogenesis of 
metabolic syndrome and T2DM.  Recent studies reported that insulin resistance is 
associated with impaired skeletal muscle oxidation capacity and reduced 
mitochondrial number and function (57).  Protecting the mitochondria from oxidative 
damage in order to improve mitochondrial function in skeletal muscle is a strategy to 
prevent and treat diseases associated with mitochondrial dysfunction (58).  
Rosiglitazone improves the suppression of adipose mitochondrial biogenesis in db/db 
and high fat diet-fed mice (59).  Pioglitazone works by reducing hyperglycemia, 
hyperlipidemia, and hyperinsulinemia in male fatty rats (60), it also improves 
mitochondrial function and stimulates mitochondrial biogenesis in human 
adipocyte/tissue in vitro (61) or human neuron-like cells (62).  Metformin has a role 
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in delaying the expression of diabetes and vascular dysfunction; it also decreases 
mitochondrial oxidative stress in Goto-Kakizaki (GK) rats (63).  However, trials 
have shown that any pharmacological therapy for T2DM, such as thiazolidinedione, 
insulin, metformin, and other oral hypoglycemic agents or combination therapy with 
or without insulin is associated with an increased risk of heart failure and body 
weight gain.  Therefore, effective treatments without obvious side effects are needed 
for preventing and treating diabetes and other metabolic syndromes (64). 
 
1.11 Mitochondrial structural and functional integrity in diabetes  
T2DM is 2-3 times more probable in individuals with diabetic mothers, and 
risk doubles if the father is diabetic.  DM is significantly linked with mitochondrial 
system, mainly mtDNA mutations.  Researchers found a 10.4 kb deletion in mtDNA 
light strand origin of replication (OL) in maternally inherited IDDM. They also found 
the A3243G mutation that is associated with mitochondrial encephalopathy in 
T2DM.  A3243G is transmitted through a carrier mother to all her children and by 80 
years of age, almost all of them will develop DM (66).  
Figure 5: Mitochondrial respiratory chain  (65) 
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Changes in mtDNA in T2DM are both qualitative and quantitative, a 35% 
decrease of mtDNA in peripheral leukocytes in T2DM patients compared to the 
control group.  Reduction was also found in presymptomatic patients who developed 
the disease two years later.  A 50% decrease in skeletal muscle mtDNA was found in 
T2DM patients but four genes encoded by mtDNA (COI, COIII, ND4 and 12s 
rRNA) had 1.5-2.0 fold increased expression.  Similar decreases have been found in 
GK T2DM rats.  Such decrease leads to impaired insulin secretion (66-67).  
Glucose stimulated insulin secretion (GSIS) is strongly linked to 
mitochondrial functional integrity.  Insulin release is inhibited by (ETC) function 
inhibitors like: rotenone, antimycin A, sodium azide, and cyanide.  In pancreatic β 
cell islets, the high capacity, low affinity receptors GluT1, and GluT2 helps the 
glucose equilibrium across the plasma membrane (67). 
Sufficient extra and intracellular glucose equilibrium is maintained by 
GLUT2 high capacity that is 100 times double the maximal rate of glycolysis.  
Cytosolic kinase (an enzyme that controls the rate of flux through glycolysis and 
pyruvate generation) phosphorylates glucose to glucose 6-phosphate.  Pyruvate 
generated from glycolysis enters the mitochondrial TCA cycle. A high level of 
glucose derived carbon enters the β cells and gets converted to mitochondrial CO2.  
Mitochondrial pyruvate is metabolized by pyruvate dehydrogenase, generating 
acetyl-CoA or pyruvate carboxylase to form oxaloacetate to ensure anaplerosis to the 
TCA cycle.  Anaplerosis can be crucial in pyruvate/malate shuttle activation causing 
an increase in cytosolic NADPH.  TCA cycle generates reducing equivalents in the 
form of NADH and FADH2 that are transformed to mitochondrial ETC with 
Adenine Triphosphate (ATP) production.  Systolic ATP/ADP ratio increase as the 
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ATP enters through adenine nucleotide translocase (ANT), this results in 
depolarization of the plasma membrane as the ATP sensitive K
+
 channels close.  β-
cell UCP-2 up regulation leads to increased ROS production, decreased ATP, ATP-
K
+
 sensitive channels closure and eventually impaired insulin secretion. In mice 
models the knockout of UCP-2 activity leads to improved β cell ATP production and 
during glucose stimulation, insulin gets secreted.  Plasma depolarization leads to 
Ca
+2 
sensitive channels opening and a sharp increase in systolic Ca
2+
, the main event 
for insulin secretion by exocytosis of secretory granules (56). 
Animal models demonstrated evidence to the intact mitochondrial ETC 
function for insulin release.  Mitochondrial DNA is needed for glucose-induced 
stimulus secretion coupling in pancreatic β cells (MIN6) of mice.  Insulin is affected 
by the glucose stimulated Ca
2+
 inhibition which is a result of mitochondrial MIN6 
depletion (56). 
1.12 Advanced glycation end-product (AGE) and diabetes 
Hyperglycemia, whether extracellular or intracellular have damaging effects 
on different organs.  Extracellular hyperglycemia leads to the formation of AGEs 
while intracellular hyperglycemia increases mitochondrial activity, protein kinase C 
(PKC), and NADPH oxidase, promoting oxidative stress complications and 
inhibition of insulin signaling pathway.   
Many researchers still consider hyperglycemia as the main factor for 
developing diabetic complications.  Hyperglycemia contributes to the formation of 
AGEs.  AGEs are formed early in embryonic life, but at a slower rate when 
compared to diabetics.  This increase is due to high levels of glucose.  AGEs are a 
heterogenous group of molecules, made from the non-enzymatic reaction between 
23 
 
reducing sugars and free amino groups originating from proteins, lipids, and nucleic 
acids.  The first product of the previous interaction is the Schiff base, which 
rearranges itself to make the amadori products (e.g. haemoglobin A1c ).  AGEs 
covalently bind to proteins, leading to altered protein structures and functions.  AGEs 
also interact with their cell surface binding receptors (RAGEs).  AGEs are 
endocytosed and either degraded or lead to the activation of pro-oxidant and 
inflammatory responses (68). 
AGEs play a role in developing micro and macro angiopathies.  High levels 
of AGEs are present in diabetics’ retinal vessels.  The higher the level of AGEs, the 
more severe the retinopathy.  Aminoguanidine is used to inhibit AGEs formation in 
diabetic patients, and help to reduce its complications. 
AGEs are found in large quantities in the peripheral nerves of diabetics.  The 
use of AGE inhibitors showed improved nerve conduction velocity and neuronal 
blood flow. 
AGEs are also found in high concentrations in diabetics’ nephrons, which 
lead to glomerulosclerosis and interstitial fibrosis due to thickened glomerular 
basement membrane and mesangial expansion.   
Animal and human studies have shown that AGEs contribute in the 
development of cardiovascular diseases.  They alter normal blood vessel and smooth 
muscle structure making them atherogenic.  AGEs also change the LDL cholesterol 
structure and make it prone to oxidation, leading to its deposition in the blood vessels 
wall (68). 
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1.13 Glucokinase mutations in diabetes 
Glucokinase, a member of the hexokinase enzymes, is located on 
chromosome 7p 15.3- 15.  It consists of 12 exons that span 45,168 bp and encode for 
a 465-amino acid protein, its molecular weight is 52,191 Da.  It is expressed in the 
pancreas, liver, brain, and endocrine cells.  Tissue specific promoters helps in 
differential regulation and transcription of different transcripts resulting in three exon 
1 (a,b,c) that differ in size. The upstream promoter is active in the pancreas and 
brain, whereas the downstream promoter is active only in the liver.  It works as a 
monomer; it helps to phosphorylate glucose on carbon 6 with Mg-ATP to form 
glucose-6-phosphate (G6P).  It is a glucose sensor in pancreatic β-cells.  Glucokinase 
is a key regulatory enzyme for insulin secretion. There are many mutations in 
glucokinase gene (GCK) (620 mutations found) and most are in the protein area 
called allosteric activator site.  Glucokinase mutations cause reduced insulin 
secretion, and lower glucose uptake by the liver leading to type 2 diabetes mellitus 
(69-70). 
 
1.14 Diseases associated with diabetes complications  
Long term diabetes increases the chances of developing many complications 
in different organs.  These complications contribute to increased diabetes morbidity 
and mortality rate.  The development of different complications is related to diabetes 
duration and glycemic control. The organs that develop diabetic complications show 
insulin independent glucose uptake.  Aldose reductase induces nicotinamide adenine 
dinucleotide phosphate (reduced form) (NADPH) to activate the pentose phosphate 
pathway, which leads to a protein kinase C–induced increase in glomerular 
prostaglandin production and loss of mesangial cell contractility, which can be a 
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cause of hyper-filtration and glomerular dysfunction in diabetes (71-72).  Impaired 
insulin and growth factor signaling, hyperlipidemia and hypertension are major 
factors for the development of diabetic complications.  The most common diabetic 
complications are macrovascular disease, nephropathy, retinopathy and neuropathy 
diseases. (71) (Figure 6). 
 
1.14.1 Diabetic Retinopathy 
Diabetic retinopathy (DR) is a microvascular complication which might harm 
the peripheral retina, the macula, or both.  It is considered a major cause of vision 
disability and blindness in diabetics.  The severity of DR ranges from non-
proliferative and pre-proliferative to the more serious proliferative DR, where 
abnormal new vessels are formed.  Neglecting vision problems in diabetics can 
Figure 6: Major complications of diabetes mellitus  (73) 
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eventually lead to partial or complete blindness through hemorrhage or retinal 
detachment (74).  Prolonged diabetics are more susceptible to DR.  A recent study in 
patients with both T1DM and T2DM, showed that after 30 years of diabetes, most of 
the patients developed some degree of DR, and more than half developed 
proliferative DR.  T1DM and people taking insulin had the highest prevalence of DR 
(75).  Another study concluded that retinopathy can occur as a late stage 
complication in T1DM, while in T2DM 20% of patients are diagnosed with 
retinopathy at the time of diabetes diagnosis (76). 
Loss of pericytes is an early marker for DR.  Pericytes are elongated 
contractile cells that surround endothelial cells of small vessels, they play a role in 
maintenance of capillary tone (ie, dilatation and constriction), and protection against 
ROS damage.  Loss of pericytes in DR would affect normal capillary constriction as 
well as new capillary generation (77). 
1.14.2 Diabetic neuropathy 
Diabetic neuropathy is due to damage in peripheral nerves.  There are two 
types of peripheral neuropathies: focal mononeuropathies and sensorimotor 
polyneuropathies. One of the most common examples is feet nerve damage, due to 
poor blood flow that increases the chances of various foot complications.  This can 
cause tingling, numbness, burning or pain which begins at the tips of the toes or 
fingers and slowly spreads upward.  Neglecting the signs and untreated cuts and 
blisters can lead to the development of serious infections; they heal slowly and may 
ultimately require toe, foot or leg amputation (78). 
Researchers found that diabetic mice fed high cholesterol diet, developed 
severe hypertriglyceridemia and advanced atherosclerosis.  The previous finding 
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suggests that lesion progression is exacerbated in obese diabetics who mostly have 
T1DM (78). 
1.14.3 Diabetic nephropathy 
Diabetic nephropathy (DN) is caused by damage to small blood vessels in the 
kidneys leading to decreased kidney efficiency or failure.  Diabetics are more prone 
to develop kidney disease.  Retaining near normal levels of blood glucose and blood 
pressure can significantly reduce the risk of kidney disease (79).  
The first sign of DN is usually microalbuminuria, which progresses to overt 
and more severe renal dysfunction and ultimately to renal failure
 
and is the leading 
cause of end-stage renal disease (ESRD) (80).  
Around 25% of people with T2DM have microalbuminuria or a more 
advanced stage of DN.
 
 Patients with DN also show thickening of glomerular 
basement membranes and glomerular hyperfiltration, which leads to mesangial 
(centre of the renal glomerulus) extracellular matrix extension and promotes 
increased urinary albumin excretion
 
and development of glomerular and tubular 
sclerosis and renal failure.  The risk factors for DN include hyperglycemia, duration 
of diabetes, age of onset, tobacco use, dyslipidemia, hypertension,
 
and obesity (75). 
1.14.4 Macrovascular complications 
DM is considered as a major risk factor for developing cardiovascular events. 
The Framingham Heart Study described diabetes as one of the causative factors 
associated with probable ratios for coronary heart disease of 1.5 and 1.8 for men and 
women, and risks for stroke of 1.4 and 1.7 for men and women, respectively (81).  
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Diabetics have a 2- to 4-fold increased possibility of developing cardiovascular 
events compared to non-diabetics (82). 
Heart disease in DM develops as a result of negative modulation at different 
levels leading to vascular (angiopathy), myocardial (diabetic cardiomyopathy), and 
intracardial nervous (autonomic neuropathy) dysfunction. Coronary artery disease 
(CAD), which eventually leads to occlusion of arteries that supply the heart, has been 
reported to be directly responsible for much of the condition of CVD in patients with 
DM.  Atherosclerotic CAD is more frequent and more severe in diabetics when 
compared to non-diabetics (83). 
Both types of diabetes mellitus (type 1 and 2) have irreversible effects on 
small and large blood vessels.  Oxidative stress and inflammation remarkably alter 
gene expression in the vasculature.  Imbalance between pro-inflammatory and 
thrombogenic systems in diabetics are key contributors in developing the pathology 
of the disease.  Eventually, the above mentioned few points lead to failure of 
vascular repair.  Macrovascular complications leading to heart attacks and strokes are 
considered the main cause of death among diabetics (84). 
CVD is very common in diabetes and particularly in T2DM, particularly in 
uncontrolled diabetes.  These patients are 2-6 times more prone to develop CVD 
compared to people with other types of diabetes.  CVD is responsible for half of the 
diabetes deaths.  It includes angina, myocardial infarction and congestive heart 
failure (85). 
1.15 Pharmacology and therapeutics in diabetes 
DM progresses to tissue or vascular damage, leading to severe complications 
such as retinopathy, neuropathy, nephropathy, cardiovascular complications and 
ulceration (86).  Thus, DM is involved in a wide range of heterogeneous diseases.  
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Medications are basically used to save lives and relieve symptoms.  Secondary aims 
of treatment are to prevent long-term diabetic complications and, by eliminating 
various risk factors, to increase durability.  T1DM treatment is mainly by insulin 
replacement, while diet control and active lifestyle are considered the basis for 
treatment and management.  Insulin supplements are also vital in T2DM when blood 
glucose levels cannot be controlled by diet, weight loss, exercise and oral 
medications. Oral hypoglycemic agents like sulphonylureas, biguanides, alpha 
glucosidase inhibitors, meglitinide analogues, and thiazolidenediones help in 
controlling T2DM.  The main role of hypoglycemic drugs is to control the 
underlying metabolic disorder, such as insulin resistance and inadequate insulin 
secretion. They are prescribed in combination with a low calorie diet and lifestyle 
changes. Diet and lifestyle help to reduce weight, improve glycemic control and 
reduce the risk of developing cardiovascular complications, which cause 70% to 80% 
of deaths among diabetics (87). 
Oral administration of stevioside improves insulin sensitivity, and seems 
suitable as an adjuvant for diabetic patients and/or those that ingest large amounts of 
fructose (88). 
Pharmacological treatments that increase brain and hypothalamic insulin 
sensitivity may provide new strategies for the prevention of dementia disorders, 
obesity, and T2DM (89). 
The increase in the intracellular deposition of triglycerides (TG) in muscles, 
liver and pancreas in subjects prone to diabetes is well documented and demonstrated 
to attenuate glucose metabolism by interfering with insulin signaling and insulin 
secretion.  The obesity often associated with T2DM is mainly central, resulting in the 
overload of abdominal adipocytes with TG and reducing fat depot capacity to protect 
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other tissues from utilizing a large proportion of dietary fat. To reduce the excessive 
fat outflow from the abdominal depots and prevent the ectopic fat deposition it is 
important to decrease the volume of central fat stores or increase the peripheral fat 
stores. This can be achieved by gastrointestinal bypass or gastroplasty, which 
decreases dietary fat absorption, or by direct means that include surgical removal of 
mesenteric fat.  Indirect treatment consists of drastic lifestyle change comprising 
both diet and exercise and pharmacotherapy that reduces mesenteric fat mass and 
activity. The first step should be an attempt to effectively induce a lifestyle change.  
Next is pharmacotherapy including acarbose, metformin, PPAR gamma, or PPAR 
gamma alpha agonists, statins and orlistat. (90) 
There are various reports suggesting the use of antioxidants in the treatment 
of diabetes. Some reports provide experimental and clinical evidence supporting 
antioxidant supplementation as a cardioprotective intervention in the setting of DM 
(91).  Other conflicting reports conclude there is no established benefit for 
antioxidant use in the management of diabetic complications (92). 
Different side effects have been associated with different hypoglycemic 
drugs.  Weight gain and hypoglycaemia with sulfonylureas, gastrointestinal (GI) 
disturbances with metformin, weight gain, GI disturbances and liver injury with 
thiazolidinediones, GI malfunctions, weight gain and hypersensitivity reactions with 
meglitinides and flatulence, diarrhea and abdominal swelling with alpha-glucosidase 
inhibitors (87). 
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1.16 Therapeutic use of Non Steroidal anti inflammatory drugs (NSAIDs) and 
aspirin in diabetes 
 
1.16.1 Type 2 diabetes as inflammatory disease 
Insulin resistance is the primary cause of T2DM.  Increased inflammatory 
response is a hall mark of obesity, diabetes and insulin resistance. Use of anti-
inflammatory drugs may be an approach to increase insulin sensitivity and energy 
metabolism.  The immune system components are different in patients with T2DM 
when compared to normal individuals.  Changes are mainly found in adipose tissue, 
liver, pancreatic islets, and circulating leukocytes.  Factors determining T2DM are 
divided into intrinsic and extrinsic factors.  Intrinsic factors include mitochondrial 
dysfunction, oxidative stress, and lipid deposition.  Extrinsic factors validity, 
cytokines, adipokines, serum fatty acids, and hypoxia, interfere with insulin 
signaling.  Surprisingly, these pathways join the common inflammation pathway. It 
is also found that diabetics show changes in some leukocytes activation, higher rates 
of apoptosis and fibrosis. Extrinsic factors affect the nuclear factor – κB (NF- κB), 
kinase β (Ikkβ), and Jun kinase (JNK) inhibitor.  As a result, insulin action gets 
inhibited by serine phosphorylation of insulin receptor substrates (IRS1, and IRS2).  
Similarly, multiple cytokine signaling suppressors are activated by cytokine proteins 
(SOCS) and adipokines, which lead to improper tyrosine kinase phosphorylation of 
IRS1, and IRS2, which finally degrade.  Consequently, intracellular insulin signal 
transduction is inhibited.  Pro-inflammatory cytokines (IL-1β, IL-6, IL-8, and IL-12) 
and chemokines are also found in insulin resistant T2DM (93).  The above variations 
support the idea that inflammation plays a role in the development of T2DM.  Trials 
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using salicylate with diabetics showed lower blood glucose levels and reduced 
disease associated complications (94). 
1.16.2 Utility of aspirin therapy in patients with type 2 diabetes 
T2DM is strongly linked with cardiometabolic syndrome (CMS), as increased 
platelets aggregation and hypercoagulability are the main causes of CMS and to 
some extent causes T2DM.  Platelets play an important role in atherosclerosis as they 
release a number of inflammatory mediators.  Patients with increased levels of 
fasting blood glucose show high platelet dependent thrombosis.  T2DM patients also 
show increased sensitivity of platelet purinergic receptors to ADP, resulting in higher 
levels of circulating platelet microaggregates that speed thrombus formation. 
For many years aspirin (from NSAID family: non-steroidal anti-inflammatory 
drugs) was known by its vasodilator, anti-inflammatory, and anti-thrombotic 
functions, it interrupts the synthesis of prostaglandins.  The synthesis happens 
through arachidonic acid oxidation that is derived from membrane phospholipids.  
After the oxidation, arachidonic acid is transformed by prostaglandin H synthase that 
is often called cyclooxygenase (COX).  COX helps in the formation of thromboxanes 
and prostacyclin, they work as vascular mediators, have a vasodynamic function, and 
platelet activity.  COX is found in two isoforms (COX1, and COX2).  COX 2 is 
induced by cytokines and associated with inflammation.  Aspirin inhibits both COX 
by irreversible serine 530 acetylation, which slows down arachidonic acid entrance 
to the active site.  Aspirin and sodium salicylate are both known inhibitors of NF-κB 
and this may be the mechanism by which they exert their anti-inflammatory effects. 
A high dose of aspirin is found to reduce glucosuria in diabetes.  High levels of free 
fatty acids lead to serine kinase cascade activation, which lead to higher levels of 
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TNFα which has a negative effect on insulin signaling.  It is also found that TNFα 
activates serine phosphorylation of IRS 1 that prevents downstream metabolic 
signaling.  One study found that aspirin can inhibit 4 out of 6 serine kinase involved 
in IRS1 phosphorylation, leading to improved insulin sensitivity by allowing 
maximum tyrosine phosphorylation and signaling by P13 kinase and protein kinase B 
pathway (95). 
Different studies have shown that aspirin therapy is a secondary prevention 
approach for cardiovascular events; clinical guidelines recommend using low-dose 
aspirin (75-162 mg/day) for the primary prevention and secondary prevention of 
CVD in individuals with risk factors.  Diabetics are considered as a high risk group, 
so they are good candidates for aspirin except for patients with contraindications (96) 
(97).  The American Diabetes Association (ADA) recommends the use of aspirin as a 
primary prevention approach in patients with diabetes who are at increased 
cardiovascular risk, including patients with a family history of CVD, hypertension, 
smoking, dyslipidemia, or albuminuria and those who are above 45 years of age (98). 
1.16.3 Aspirin side effects and aspirin resistance 
Nevertheless, due to the action of aspirin on cyclooxygenase (COX), it is 
associated with upper GI complications including ulcers and bleeding.  The severity 
of the side effects is less with low-dose aspirin compared with non-selective, 
NSAIDs.  Co-administration of a gastro-protective agent like the proton pump 
inhibitors (PPIs) is useful for decreasing the chance of developing upper GI 
associated with use of low-dose aspirin.  Treating existing H. pylori also helps to 
reduce the risk of these side effects, especially in those at high risk (96). 
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Aspirin resistance is the failure of aspirin to decrease platelet production of 
thromboxane A2.  High degrees of aspirin resistance can be associated with 
increasing risk of cardiovascular events.  Laboratory tests of platelet thromboxane 
A2 production or platelet function that is dependent on platelet thromboxane 
production can be used as a measure of aspirin resistance. Possible causes of aspirin 
resistance can be insufficient dose, drug interactions, genetic polymorphisms of 
COX-1 and other genes needed for thromboxane biosynthesis, upregulation of non-
platelet sources of thromboxane biosynthesis, and increased platelet turnover.  
Tackling the reason of aspirin resistance can help in overcoming the problem.  
Recent research is focused on defining aspirin resistance, developing dependable 
tests for it, and measuring the risk of associated cardiovascular events (99). 
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1.17 Aim of the present work 
Metabolic complications and atherosclerotic vascular disease is a major cause 
of premature morbidity and mortality in obesity and chronic T2DM. Increased 
oxidative stress, inflammatory responses and mitochondrial dysfunction have also 
been implicated in diabesity. Aspirin and other NSAIDs have been used in many 
clinical and experimental trials for the prevention of diabetes, cancer, obesity and 
atherosclerotic cardiovascular complications. We therefore, plan to investigate the 
effects of aspirin on molecular and metabolic targets altered in diabetes using 
expiremental model of T2DM.  The GK rat is a spontaneous non-obese animal 
experimental model of T2DM. This strain was developed by selective breeding of 
glucose intolerant Wistar rats over many generations. The GK rats exhibit decreased 
β-cell numbers and function which is accompanied by mild hyperglycemia, impaired 
glucose-induced insulin secretion, marked glucose intolerance, peripheral insulin 
resistance and chronic inflammation (100-102).  Despite the mild hyperglycemia 
several manifestations of diabetes complications have been demonstrated in this 
model (103-105). 
Growing evidence has linked T2DM with low-grade systemic inflammation. 
Thus, the GK rat represents a good animal model for studying human T2DMM 
pathophysiology and the effects of therapeutic options such as the use of aspirin or 
other NSAIDs. It is possible that existing low-grade systemic inflammation can be 
suppressed by experimental strategies aimed at blocking the production or action of 
proinflammatory signaling pathways, thereby treating T2DM. 
Since the objective of the present study was to elucidate the mechanism of 
aspirin action in altering metabolic and molecular targets affected in diabetes, we 
intended to avoid gastric toxicity caused by oral administration of aspirin, and 
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therefore we have selected to administer a low dose aspirin (100 mg/Kg body 
weight) intraperitoneally for 5-weeks in young GK T2DM rats.  
1.18 Hypothesis 
 Since inflammation, oxidative stress and mitochondrial dysfunction appears to 
be hallmarks of diabetes in general and T2DM in particular, we plan to elucidate the 
molecular and biochemical mechanisms of action of aspirin on the pathophysiology 
and metabolic complications of T2DM using insulin resistant hyperglycemic GK 
rats.  Aspirin and other NSAIDs have been used in clinical and experimental trials 
for the prevention of diabetes, obesity and other complications.  Our specific aims 
are to find wither ASA: 
1. Improves pancreatic islet β-cell integrity and function. 
2. Improves β-cell insulin secretory ability and regulate glucagon synthesis. 
3. Improves insulin signaling. 
4. Improves glucose uptake and energy metabolism in target tissues. 
5. Improves mitochondrial function, oxidative stress and improve antioxidant 
redox homeostasis. 
6. Alters drug metabolism and detoxification in the tissues in diabetic rats. 
ASA might be involved in altering the molecular and metabolic targets affected 
in T2DM. 
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Chapter 2: Methods 
 
2.1 Chemicals 
Aspirin, bovine serum albumin (BSA), picric acid, paraformaldehyde, 
trisodium citrate, potassium phosphate,cytochrome c, reduced glutathione (GSH), 
oxidized glutathione  (GSSG), 5,5’-dithio-bis(2-nitrobenzoic acid), 1-chloro 2,4-
dinitrobenzene (CDNB), cumene hydroperoxide, dimethylnitrosamine (DMNA), 
erythromycin, glutathione reductase, NADH, NADPH, coenzyme Q2, antimycin A, 
dodecyl maltoside, sodium succinate, lucigenin and ATP Bioluminescent cell assay 
and Hexokinase colorimetric assay kits were purchased from Sigma-Aldrich Fine 
Chemicals (St.Louis, MO, USA). 2’, 7’-Dichlorofluorescein diacetate (DCFDA) was 
procured from Molecular Probes (Eugene, OR, USA). Polyclonal antibodies against 
insulin and glucagon were purchased from Dako, Denmark, while those against Akt, 
p-Akt, JNK, p-JNK and β-actin were purchased from Santa Cruz Biotechnology Inc. 
(Santa Cruz, CA, USA). Antibodies against PPAR-γ was purchased from Abcam 
(Cambridge, UK) while that against 4-HNE was from Oxis Int. Inc. (Portland, OR, 
USA). FITC and TRITC conjugated secondary antibodies were purchased from 
Jackson Immuno-research Laboratories (West Groove, Pa, USA). Kits for insulin 
were purchased from EMD Millipore Corporation (Billerica, MA, USA), PGE2 from 
Arbor Assays (Michigan, USA), total nitrate/nitrite from R & D Systems, Inc., 
(Minneapolis, MN, USA), SOD and GDH from Abcam (Cambridge, UK), LPO kit 
from Oxis Int. Inc. (Portland, OR, USA).  Reagents for SDS-PAGE and Western blot 
analyses were purchased from Gibco BRL (Grand Island, NY, USA) and Bio Rad 
Laboratories (Richmond, CA, USA).   
                    stsssssاOssاc.ss ssaا- OPc- ssas     
38 
 
2.2 Animals 
Ten male GK rats (weighing 100-120 g) were procured from Taconic 
(Germantown, NY, USA) at five weeks of age.  Ten male Wistar rats of similar age 
and weight were procured from the Animal House Facility of College of Medicine & 
Health Sciences, United Arab Emirates University (U.A.E) and were used as non-
diabetic controls to evaluate the progression of diabetes in GK rats. All animals were 
maintained under standard laboratory conditions including a 12-hour light/dark cycle 
with free access to food, water and libitum. Approval for this project was obtained 
from the Animal Ethics Committee, College of Medicine & Health Sciences 
(Protocol Ref#A1-13); U.A.E and all the animals were used following the safe 
practice for animals in research guidelines as stipulated by NIH, USA. Body weights 
and blood glucose levels (One Touch Ultraglucometer, LifeScan Inc, U.S.A) of the 
animals were regularly measured. 
 
2.3 Animal treatment, tissue homogenisation and glucose tolerance test 
After 4 months, the GK rats (avg. body wt. 319g) showed signs of 
hyperglycemia (fasting blood glucose 80-90 mg/dl) while the control Wistar rats 
(avg. body wt. 323g) had a fasting blood glucose level of 50-60 mg/dl. The animals 
were then divided into four subgroups, each containing 5 animals. Two subgroups of 
GK and Wistar control rats were injected intraperitoneally with 100 mg ASA/kg 
body weight/ day) for 5 weeks. This experimental dose and time points were selected 
based on the published reports in previous studies, using diabetic models including 
GK rats (106-112). 
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In order to avoid gastric toxicity caused by oral administration of aspirin, we 
administered aspirin intraperitoneally.  
Towards the end of the experiment, the animals were subjected to a glucose tolerance 
test. Briefly, after an overnight fast, animals were injected with glucose (2g 
glucose/kg body weight) intraperitoneally. Blood samples were collected from the 
tail vein at time 0 (prior to the glucose load), 60 and 120 minutes after the glucose 
challenge and glucose levels were measured. 
At the end of 5 weeks, animals were sacrificed by decapitation and blood was 
collected from the jugular vein. Pancreas and the heart from the animals were 
quickly excised and a portion of these were fixed in Zamboni's solution and 
processed for immunofluorescence studies. The rest of the tissues were stored at -80 
o
C until further analysis. Portions of the tissues were homogenized (25 % w/v) in H-
medium (70 mM sucrose, 220 mM mannitol, 2.5 mM HEPES, 2 mM EDTA and 0.1 
mM phenylmethylsulfonyl fluoride, pH 7.4) and used for isolating mitochondria, 
cytosol and microsome by differential centrifugation.  Protein concentration in the 
serum and sub-cellular fractions was measured using Bio-Rad reagent as described 
before (113-115). 
 
2.4 Serum analysis  
            Blood samples collected from the jugular vein after decapitation were 
transferred into a plain tube.  Samples were centrifuged at 4000 rpm for 10-15 min 
and the serum was used to assay key organ function tests, cholesterol and 
lipoproteins, glucose levels and uric acid using the COBAS® INTEGRA 400 plus 
auto-analyzer (Roche, Basel, Switzerland). Insulin, PGE2, total NO and SOD assays 
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were also performed in the serum samples using appropriate kits as suggested in 
vendor’s protocols and as described before (116-117). 
2.5 Insulin assay 
Serum insulin level was measured using a non-radioactive quantitative insulin 
ELISA kit (Cat# EZRMI-13K).  Briefly, serum samples were loaded onto microtiter 
plates that were pre-coated with monoclonal mouse anti-rat insulin antibodies to 
capture the insulin molecules, followed by addition of biotinylated polyclonal 
antibodies that bind to the captured insulin.  The addition of horseradish peroxidase 
then binds to the immobilized biotinylated antibodies. The activity of horseradish 
peroxidase in the presence of 3,3´,5,5´  tetramethylbenzidine was measured at 450 
nm. The increase in the absorbency was proportional to the amount of captured 
insulin in the sample.  The concentration of insulin was calculated from the standard 
curve. 
2.6 Detection of insulin/glucagon by immunoflurescence staining 
Immunofluorescence (IF) is a technique that employs fluorescent-labeled 
antibodies to detect specific target antigens.  It is commonly used in both scientific 
research and clinical laboratories. In our research we used indirect 
immmunoflurescence which utilizes a two-step technique (118).  Using a primary 
unlabeled antibody that binds to the protein of interest (insulin, or glucagon), 
followed by loading a fluorophore-labeled secondary antibody (directed against the 
Fc region of the primary antibody) to detect the first antibody.   
Immunoflurescence staining was performed on pancreatic tissue sections, cut 
to 5 μm thickness.  Sections were dewaxed by immersing in xylene (two changes) 5 
minutes each at room temperature, followed by rehydration in descending 
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concentrations of ethanol (100 %, 95 %, 70 %, and 50 %) for 3 minutes each, 
washing with  distilled water, followed by Antigen retrieval using citrate buffer (pH 
6).  The slides were then incubated for 1 min in the microwave using power 10, 
followed by 10 minutes incubation at power 1 and allowed to cool down to room 
temperature for 30 minutes. Slides were washed three times in PBS before incubating 
with blocking reagent at room temperature for 45 minutes.  This was followed by the 
application of the first primary anti-insulin antibody (polyclonal guinea pig anti 
insulin diluted at 1:2000), which was incubated overnight at 4 °C followed by PBS 
wash (three changes, for 5 minutes each).  First secondary antibody (anti-guinea pig 
FITC diluted 1:100) was added and incubated for one hour at room temperature.  
After a PBS wash (three changes, for 5 minutes each), the second primary antibody 
was added (pre-diluted polyclonal rabbit anti human glucagon), and incubated 
overnight at 4 °C, followed by Phosphate Buffered Saline (PBS) wash (three 
changes, for 5 minutes each).  The second secondary antibody (Glucagon: anti-rabbit 
TRITC diluted 1:100) was added and incubated for one hour at room temperature 
followed by PBS wash (three changes, for 5 minutes each).  Finally slides were 
washed with PBS (three changes, 5 minutes each) before mounting with CTTI-
Fluore mounting media. Slides were examined using a fluorescence microscope.  
Sections were studied using AxioCam HRc digital camera with AxioVision 3.0 
software (Carl Zeiss, Oberkochen, Germany) fixed with z-plane fluorescence.  
Contrast and brightness of sections were adjusted and images were merged using 
image J 1.48V 
2.7 Prostaglandin E2 assay 
Aspirin has been known for years for its vasodilator, anti-inflammatory, and 
anti-thrombotic functions.  Its main function is to inhibit the synthesis of 
42 
 
prostaglandins.  PG synthesis happens through arachidonic acid oxidation that is 
derived from membrane phospholipids.  After oxidation, arachidonic acid becomes 
transformed by the action of prostaglandins H synthase which is better known as 
cyclooxygenase (COX) (119). 
Prostaglandin (PG) E2 is the most produced PG with different actions. PGE2 
is usually considered as an immunosuppressant as it inhibits T cell activation in vitro. 
However, in vivo its immunosuppressant action has been unclear. Recently, several 
researchers have found that PGE2 facilitates expansion of the Th17 subgroup of T 
helper cells of both human and mouse through elevation of cAMP via PGE receptors, 
EP2 and EP4 (120). 
PGE2 was measured in the serum using the DetectX high sensitivity 
immunoassay kit (Cat # K018-HX1).  Briefly, standards or diluted samples were 
added to a microtiter plate coated with an antibody that captures mouse IgG. A PGE2 
– peroxidase conjugate was added followed by a monoclonal antibody to PGE2.  
Finally the substrate was added to react with the bound PGE2 conjugate and the color 
generated was read at 450 nm using a microtiter plate reader. PGE2 concentration 
was calculated from the standard curve. 
2.8 Measurement of nitric oxide production 
Nitric oxide (NO) is synthesized endogenously by an enzyme nitric oxide 
synthase (NOS) from the precursor L-arginine (121).  NO is a gaseous free radical 
with a short half-life of a few seconds or less. Due to its instability, it is difficult to 
measure.  Therefore, the levels of the more stable NO metabolites, nitrite (NO2
-
) and 
nitrate (NO3
-
), have been used to indirectly measure NO. Total NO was measured 
using the nitric oxide kit (R &D systems, Inc.) (Cat # ab65328). This assay estimates 
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nitric oxide concentrations based on the enzymatic conversion of nitrate to nitrite by 
nitrate reductase, followed by the colorimetric detection of nitrite as an azo dye 
product of the Griess reaction. The Griess reaction is a two-step diazotization 
reaction where acidified NO2
- 
produces a nitrosating agent which reacts with 
sulfanilic acid producing a diazonium ion. This ion then couples to N-(1- naphthyl) 
ethylene diamine forming the chromophoric azo-derivative that absorbs light at 540 – 
570 nm.  The reaction mixture containing the reaction diluents, serum samples from 
treated and untreated groups, NADH, and diluted nitrate reductase was incubated for 
30 mins at room temperature. The reaction was started by adding Griess reagents І 
and ІІ, and after an additional incubation for 10 minutes at room temperature, the 
absorbance was read at 546 nm.  NO concentration in the samples was calculated 
from the standard curve. 
2.9 Measurement of Superoxide dismutase     
ROS, like superoxide radicals, are involved in the pathogenesis of many 
diseases.  Almost 3 to 10 % of the oxygen used by tissues is converted to its reactive 
intermediates that affect the functions of cells and tissues.  Superoxide dismutase 
(SOD) is an important anti-oxidative (122) enzyme that catalyzes the conversion of 
single electron reduced species of molecular oxygen to hydrogen peroxide and 
oxygen (O2·
-
 + O2·
-
 + 2H
+
 → O2 + H2O2) (123).   
SOD was measured using Abcam’s Superoxide activity assay kit 
(Colorimetric) (Cat # ab65354).  It is a sensitive kit that uses a substrate, WST1 
which produces a water soluble formazan dye on reduction with superoxide anion.  
Reduction rate is linearly related to the xanthine oxidase (XO) activity and is 
inhibited by SOD.  Thus, inhibition activity of SOD was detected using this method. 
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Briefly, serum samples and tissue homogenates were treated with WST in the 
presence of the enzyme working solution in the reaction buffer for 20 mins at 37 
o
C. 
The absorbance was read at 450 nm using a microplate reader and the percentage 
inhibition rate calculated. 
2.10 Assay for Reactive oxygen species  production  
Oxidative stress has a major role in the development of DM.  Oxidative stress
 
in the tissues was evaluated by measuring superoxide production. Two different 
methods
 
were used: the lucigenin-enhanced chemiluminescence
 
method for NOX 
detection and the DCFH-DA method for ROS detection.  
 NAD(P)H-dependent lucigenin-enhanced chemiluminescence for detection 
of  NOX was carried out using the method of Li Y et. al. (124).  Briefly, around 50 -
100 µg of tissue homogenates were used with 0.1 M KPi buffer (pH 7.4), and 1mM 
lucigenin and 10 mM NADPH was added. Chemiluminescence
 
was instantly 
measured using the Turner
 
Designs TD-20/20 luminometer for an integration time of 
60 s.  Controls were used and blank reading was subtracted from the final values 
expressed.  
SOD
XO 
O2+H2O    
   
2O2
- 
Xanthine 
O2+H2O       
H2O2 
Uric acid         
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ROS generation was also measured by the dichlorofluorescein
 
method using a 
cell permeable probe DCFH-DA (2’, 7’-dichloro fluorescein diacetate) that measures 
peroxides. DCFH-DA is a stable compound that diffuses into cells and is hydrolyzed 
by intracellular
 
esterases to produce DCFH which remains within the cells.  DCFH is 
rapidly oxidized
 by peroxy radicals to the highly fluorescent compound, 2’, 7’- 
dichlorofluorescein (DCF). Briefly, mitochondrial samples were incubated with 5 
µM of stable
 
non-fluorescent DCFH-DA for 30 min at 37 
◦
C in 0.1 M Kpi buffer, pH 
7.4. The reaction was stopped using ice-cold 0.1 M Kpi buffer, containing 0.1 % 
Triton X-100 and was read in a spectrofluorimeter at an excitation wavelength of 488 
nm and an emission wavelength of 525 nm.  
2.11 Lipid peroxidation assay  
Lipid peroxidation (LPO) is the oxidative degradation of lipids.  Free radicals 
pull an electron from the lipids cell membrane, leading to cell damage. The LPO 
assay was carried out using the LPO-586™ assay kit. 
The LPO-586™ assay is based on the reaction between a chromogenic 
reagent, N-methyl-2-phenylindole, and MDA and 4-hydroxyalkenals at 45 °C. One 
molecule of either MDA or 4-hydroxyalkenal reacts with 2 molecules of the reagent 
to produce a stable chromophore with maximal absorbance at 586 nm.  Briefly, the 
standards, samples and reagent were mixed followed by the addition of 37 % HCl, 
incubated at 45 °C for 60mins, centrifuged and the clear supernatant read at 586 nm. 
2.12 Measurement of total Glutathione sulfhydryl 
Glutathione (GSH, γ-glutamylcysteinylglycine), the primary non-protein 
sulfhydryl in the cells of most aerobic organisms is the body's major antioxidant 
(125).  It is a tripeptide, that is formed from three amino acids; glutamic acid, 
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cysteine, and glycine (126).  It plays a major role in cellular metabolism. For 
example, in the detoxification of certain arenes, or as a cofactor in the biosynthesis of 
leukotriene and prostaglandin, it is a major antioxidant, that protects cells from free 
radicals. Moreover, it is an essential electron donor to glutathione peroxidase in the 
reduction of hydroperoxides (126).  Glutathione is found in the reduced sulfhydryl 
(GSH) and oxidized disulfide (GSSG) states.  In healthy cells and tissues, it is 
retained in the reduced state (GSH) by the action of glutathione reductase (127).  
GSH levels were measured as protein-free sulfhdryl content using Ellman’s 
reagent (128) with few modifications from the method of Tietze (127).  The assay 
depends on the enzymatic recycling method, via using glutathione reductase for 
GSH quantification.  The general thiol reagent, 5-5'-dithiobis [2-nitrobenzoic acid] 
(DTNB, Ellman's Reagent) reacts with the sulfhydryl group of the GSH and 
produces a yellow colored 5-thionitrobenzoic acid (TNB) and GS-TNB (between 
GSH and TNB). This is then reduced by glutathione reductase and β-nicotinamide 
adenine dinucleotide phosphate (β-NADPH), to produce more TNB, thus recycling 
the GSH. The TNB production rate is directly related to this recycling reaction, 
which is directly proportional to the concentration of GSH in the sample. TNB 
absorbance measurement at 412 nm gives an accurate estimation of GSH in the 
sample. The glutathione reductase reduces all oxidized GSH (GSSG) present in the 
reaction mixture or formed from the mixed disulfide reaction of GSH with GS-
TNB to GSH.  Therefore the assay measures the total glutathione in the sample. 
Briefly, the reaction mixture (total volume of 1 ml) contained 143 mM NaPi/ 
6.3mM EDTA, pH 7.5, DTNB, 20 mM NADPH and 30-40- µg 
cytosolic/mitochondrial protein which was precipitated with 10 % 5-sulfosalicylic 
acid. 
47 
 
The reaction was initiated by the addition of glutathione reductase for a 
period of 2mins at 30 seconds interval.  GSH amounts in the sample were estimated 
by running standards of known concentration under the same conditions. 
2.13 Measurement of Glutathione s-transferases activity 
Glutathione S-transferases (GST), a phase ІІ detoxification enzyme exists in 
different isoforms. It plays an important role in the protection against various 
toxicants by catalyzing the conjugation of glutathione with the reactive electrophilic 
metabolites and xenobiotics (129).  Glutathione S-transferases (GSTs) can reduce 
lipid hydroperoxides through their Se-independent glutathione peroxidase activity 
and these enzymes have the ability to detoxify lipid peroxidation end products such 
as 4-hydroxynonenal (4-HNE).  Earlier studies together with results of recent studies 
in our laboratory suggests that lipid peroxidation products, particularly 
hydroperoxides and 4-HNE, are involved in the mechanisms of stress-mediated 
signaling, and can be controlled by the alpha class GSTs through the regulation of 
the intracellular concentrations of 4-HNE (130).   
The cytosolic and mitochondrial GST activities were measured using 1 
chloro-2, 4-dinitrobenzene (CDNB) according to the method of Habig et al. (131), 
with few modifications. Briefly, the reaction mixture contained 0.3 M potassium 
phosphate
 
buffer, pH 6.5, 1.0 mM GSH, 1.0 mM CDNB,
 
and 40-50 µg mitochondria 
or cytosol. The reaction was carried out at 25°C, and the
 
change in absorbance at 
340nm was monitored for 2 mins
 
using a spectrophotometer (model DU-70, 
Beckman). All initial rates
 
were corrected for the background non-enzymatic 
reaction. One unit
 
of activity is the formation of 1 µmol product min
-1
 at 25°C 
(extinction coefficient at 340 nm = 9.6 mM
-1
 cm
-1
 for CDNB). 
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2.14 Glutathione peroxidase activity (GSH-Px) 
GSH-Px is a major antioxidant in the cellular system.  It plays an important 
role in the detoxification of peroxides, thereby preventing cellular lipid peroxidation. 
GSH-Px uses glutathione to reduce hydrogen peroxide to
 
water and lipid peroxides to 
alcohol.  Glutathione peroxidase protects cells from oxidative damage by consuming 
free peroxide, in the presence of selenium as a cofactor. Considering the presence of 
non-selenium enzymes, cumene hydroperoxide was used as the substrate in order to 
measure the total GSH-Px (Se and non-Se enzymes) activity. This was done by 
NADPH oxidation using a coupled
 
reaction system that contains glutathione, 
glutathione reductase,
 
and cumene hydroperoxide. The reaction below demonstrates 
the action of GSH-Px that oxidizes 2 moles of reduced GSH to oxidized GSSG  
                                             GR 
2GSH       +       H2O2                                GSSG +   2H2O2 
Glutathione Reductase (GR) reduces the oxidized glutathione to complete the cycle: 
                                                   GR 
GSSG + NADPH +  H
+ 
                             2GSH   +    NADP
+
 
The oxidation of NADPH to NADP
+
 leads to a decreased absorbance at 340 
nm. The rate of decrease in absorbance is directly proportional to the glutathione 
peroxidase activity.  The reaction mixture (total volume of 3 ml) contained 50 mM 
KH2PO4/5 mM EDTA buffer, pH 7.0, 28 mM NADPH, 3.75 mM NaN3, 0.5 mM 
GSH and 1 unit of GR that was incubated for 10 minutes at 25 
ͦ
C before adding 50-
100 µg of mitochondrial or cytosolic protein. The reaction was initiated by adding 
0.2 mM cumene hydroperoxide,
 
and measured using the spectrophotometer at 340 
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nm for 2-5 minutes. Results are expressed as nmol/min/mg protein, using the 
extinction coefficient of NADP (6.22 mM
-1
 cm
-1
). 
2.15 Assay for cytochrome P450  
The cytochrome P450 enzymes form the phase ІІ detoxification enzymes, 
which exists in different isoforms. They play an important role in detoxification and 
protection against a wide variety of xenobiotics and various drugs.  They are very 
important for metabolizing many endogenous compounds and for their detoxification 
(132).  The CYP 2E1 isoenzyme helps in the reduction of oxygen to superoxide and 
peroxide which is important in lipid peroxidation (133).  The activity of CYP 2E1 
was measured as described by Czygan et al. (134).  Briefly, the reaction mixture  
composed of assay buffer (50 mM Kpi, pH 7.4 and 10 mM MgCl2), 1 mM NADPH, 
4 mM NDMA (N-nitrosodimethylamine N-demethylase), and 100-200 µg 
microsomal protein were incubated at 37 
◦
C for 30 minutes. 25 % ZnSO4 and 
saturated Ba (OH) 2 solution were added to stop the reaction. After centrifugation, an 
equal amount of NASH reagent (consisting of ammonium acetate, acetyl acetone and 
acetic acid) was added to the supernatant, heated at 60
 ◦
C for 30 minutes and then left 
to cool in ice water. CYP 2E1 activity was determined using a spectrophotometer set 
at 412 nm and calculated using a standard curve plot using different concentrations 
of formaldehyde run under the same conditions. 
Another isoenzyme from the CYP 450 family is the CYP 3A4, which is the 
most abundant enzyme found in the liver and the intestine.  Similar to the CYP 2E1, 
is vital in oxidizing xenobiotics, such as toxins or drugs. It plays an important role in 
the metabolism of approximately half the drugs in use today.  Its catalytic activity 
variation is important in issues of bioavailability and drug-drug interactions (135). 
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The assay of CYP 3A4 activity was similar to that of CYP 2E1, except that 
erythromycin was used as the substrate for this isoenzyme. 
2.16 Assay of mitochondrial respiratory complexes  
Mitochondrial complexes are located in the mitochondrial inner membrane 
and make up the ETC system, which plays a major role in the production of ATP, the 
main energy intermediate in living organisms.  
Mitochondrial complex I, also known as NADH:quinone oxidoreductase or 
NADH dehydrogenase is the first enzyme (Complex I) in the mitochondrial ETC.  It 
works by transferring electrons from reduced Nicotinamide adenine dinucleotide 
(NADH) to coenzyme Q (CoQ).  This complex also translocates protons, helping to 
provide the electrochemical potential involved in ATP production.  Respiratory 
complex II oxidizes succinate to fumarate in the Krebs cycle and reduces ubiquinone 
in the electron transport chain (136). Complex III transfers the electrons from 
CoQH2 to reduce cytochrome c that is the substrate for complex IV. Complex IV, 
also known as cytochrome c oxidase transfers four electrons from four molecules of 
cytochrome c to molecular oxygen (O2) to produce two molecules of water (H2O). 
Together, it moves four protons across the membrane, producing a proton gradient to 
produce ATP. 
Complex І specific activity was measured by following the decrease in 
absorption due to the oxidation of NADH at 340 nm (ε = 6.81 mM-1cm-1).  0.13 mM 
NADH, 65 mM ubiquinone and 2 µg/ml of antimycin were added to the assay 
mixture containing 50 mM Kpi, pH 7.2 and 5 mM MgCl2 to make a final volume of 
1 ml. 10-20 µg mitochondria was added and the NADH: ubiquinone oxidoreductase 
activity was measured for 2 minutes, then rotenone (2 µg/ml) was added and the 
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activity was measured for an additional 2 minutes. Complex І activity is the rotenone 
sensitive NADH: ubiquinone oxidoreductase activity. 
Complex II (succinate-ubiquinone oxidoreductase) and Complex III 
(ubiquinol-cytochrome c oxidoreductase) activities were measured by monitoring the 
reduction of cytochrome c at 550 nm (ε = 19.1 mM-1cm-1).  1M succinate was used 
as a substrate in the assay that comprised of 50 mM KPi buffer, pH7.2, 5 mM MgCl2 
and 2.5mM oxidized cytochrome c.  Around 10-20 µg of mitochondrial protein was 
added and the Complexes II, III activities were measured for 2 mins at 550 nm. 
Rotenone (2 µg/ml) and 0.1 M sodium azide were added to block the activities of 
Complex I and Complex IV respectively. The activity was expressed as nmol/mg 
protein. 
Complex IV activity was measured by monitoring the oxidation of reduced 
cytochrome c at 550 nm (ε = 19.1 mM-1cm-1). The assay was performed using 10 µg 
of mitochondrial protein at 550 nm using 50 µM cytochrome c (reduced) as
 
the 
donor. Reduced cytochrome c
 
was prepared fresh on the same day, using 0.1 M 
dithiothreitol
 
(DTT) as a reducing agent. The
 
assay mix contained 10 mM Tris-HCl 
pH 7.0, 120 mM KCl, and 250
 
mM sucrose in a final volume of 1 ml.  1 mM lauryl 
maltoside (LM) was added to make the external
 
mitochondrial membrane permeable. 
The initial rate of cytochrome c reduction was used to calculate the activity. 
Complex IV activity is expressed as nmol /mg protein. 
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2.17 Measurement of cellular adenosine triphosphate levels 
Adenosine triphosphate (ATP) has many essential roles in the cells. It is the 
main intermediate donor of energy needed for most of the energy-consuming 
anabolic and catabolic activities in the cell.  ATP is present in all metabolically 
active cells. Thus it is used as a marker to evaluate cell viability.  Its concentration 
rapidly declines when cells undergo necrosis or apoptosis.  Total cellular ATP was 
measured by bioluminescence using the ATP-bioluminescent
 
somatic cell assay kit 
(Sigma, Cat # FLASC).  The assay is based on the following reaction: 
 
The intensity of the light emitted is proportional to the amount of ATP and is 
measured using a luminometer.  The amount of ATP in the samples was expressed as 
LU/mg protein. Briefly, 100-200 µg of mitochondrial protein were lysed with 
somatic cell releasing reagent that leads the release of cellular ATP by altering 
membrane
 
permeability. The free ATP reacts with Luciferin-Luciferase in the 
reaction mix and the light released was
 
measured using a Turner Designs 20/20 
luminometer. The emitted light was proportional to the ATP concentration in the 
sample.          
 
 
ATP +  D-luciferin  + O2                                 AMP+ PPi + oxyluciferin + CO2 +    
 
light
LUCIFERASE + Mg2
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2.18 Hexokinase assay 
Hexokinase is an insulin sensitive enzyme and it is the first enzyme in the 
glycolytic pathway.  It uses ATP to catalyse the phosphorylation of aldo- and keto-
hexoses to hexose-6-phosphate. There are multiple isoenzymes of hexokinase (HK-I, 
II, III and IV), they differ in their kinetic and regulatory properties and distribution in 
the body.  Studies have shown alterations in hexokinase in different diseases such as: 
x-linked muscular dystrophy, hemolytic anemia, and cancer (137).  
Hexokinase activity was measured using a hexokinase colorimetric assay kit 
from Sigma –Aldrich (Cat # MAK091).  The enzyme activity was determined by a 
coupled enzyme assay, in which glucose was converted to glucose-6-phosphate by 
hexokinase, which, in turn, was oxidized by glucose-6-phosphate dehydrogenase to 
produce NADH. This, in turn, reduces a colorless probe producing a colorimetric 
(450 nm) product proportional to the available hexokinase activity.  The amount of 
NADH produced was determined from the standard curve. One unit of hexokinase 
enzyme is the amount that will produce 1.0 µmole of NADH per minute at pH 8.0 at 
room temperature. 
2.19 Glutamate dehydrogenase assay 
Glutamate dehydrogenase (GDH) is a mitochondrial enzyme, which plays a 
vital role in controlling insulin secretion. Nevertheless, it is not known if GDH 
expression levels in β-cells is rate limiting for the secretory response to glucose. 
GDH also plays an important role in controlling glutamine and glutamate oxidative 
metabolism (138). 
Abcam’s glutamate dehydrogenase kit (Cat # ab 102527) was used to detect 
GDH in the mitochondrial samples.  It is a sensitive method to detect the enzyme 
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activity, as low as 0.01 mU.  In this assay, GDH in the sample consumes glutamate 
as a specific substrate and generates NADH, resulting in a proportional color 
development, which is read colorimetrically at 450 nm.  Briefly, the mitochondrial 
samples and standards were incubated with the GDH developer and NADH for 30 
mins to 2 h at 37 
o
C and the absorbance measured at 450 nm at 5 min intervals. The 
amount of NADH generated was determined from the standard curve. 1 unit is the 
amount of enzyme that will generate 1.0 umol of NADH/min at pH 7.8 and 37 
o
C. 
 
2.20 SDS-PAGE and Western Blot analysis  
50 µg protein from the pancreatic and heart total extract and 10-20 µg protein 
from serum samples from all the four groups were separated by 10 % SDS-PAGE.  
This separates the proteins according to their molecular size (139).  The separated 
proteins were then electrophoretically transferred to a membrane (nitrocellulose 
paper) by Western Blotting (140).   Membranes were blocked using 5 % non-fat milk 
in TBS-0.05 %
 
Tween-20; it is an essential step to avoid any non-specific antibody 
binding.  The membranes were immunoblotted with the antibodies to the proteins of 
interest, as described before (141) after which the membranes were treated with a 
secondary antibody for 1 hour at room temperature.    Blots were then developed 
using ECL Plus Western Blotting Luminol Reagent kit(cat #), scanned and 
quantitated using the ImageJ 1.48 software.  β-actin was used as the loading control.                   
2.21 Statistical analysis 
Data analysis was performed using SPSS software, version 21.  All results are 
expressed as means ± SEM of at least three to four determinations. Statistical 
significance of the data was assessed using analysis of variance followed by LSD’s 
post-hoc analysis. P values ≤0.05 were considered statistically significant. 
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Chapter 3: Results 
 
3.1 Effect of ASA on body weight 
Aspirin treatment marginally lowered the body weight in control and GK rats. 
The control rats which had an average weight of 325 g before treatment with ASA 
showed a weight of around 295g after aspirin treatment. Similarly GK rats which 
showed an average weight of around 343 g were marginally reduced to around 326 g 
after ASA treatment.  Although more planned studies are needed to further confirm 
this observation. None the less, our study may suggest an increased utilization of 
energy after aspirin treatment may be a cause of weight loss. 
 
3.2 Effect of ASA on blood glucose and insulin levels 
The fasting blood glucose level (Figure 7A) in GK rats was significantly 
higher compared to control rats, and was reduced modestly (17 %) when treated with 
ASA from (14.7 mM to 12.5 mM). This could be due to more efficient glucose 
uptake and or utilization in ASA-treated GK rats.  Similarly, blood insulin (Figure 
7B) was significantly elevated (> 2-fold) in GK rats and ASA treatment significantly 
reduced the levels. No significant changes in blood glucose or insulin levels were 
observed in control non-diabetic rats treated with ASA. These results may suggest 
increased energy expenditure in ASA-treated diabetic rats which is presumably due 
to increased insulin sensitivity and responses in peripheral tissues. 
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Figure 7: Effect of aspirin treatment on blood glucose and insulin levels. 
 
 
 
 
 
 
3.3 Effect of aspirin on glucose tolerance 
Improved glucose tolerance was observed at 60-120 mins after I.P. 
administration of 2g glucose/ kg body weight in ASA treated rats. The diabetic GK 
rats showed a more significant improvement (20-30 %) compared to control rats 
(Figure 8). No significant alterations in glucose tolerance were observed in control 
 Insulin was measured in control Wistar (C) and GK rats treated with/without ASA 
(n=5). Serum separated from the blood of the rats was subjected to analysis for 
glucose (A) on the COBAS
®
 INTEGRA 400 plus auto-analyzer and insulin levels 
(B) were measured using the ELISA kit as described in the Materials and Methods. 
Results are expressed as mean + S.E.M. from three independent experiments and 
asterisks indicate significant difference. (** indicates p< 0.001 compared to 
control, ∆ indicates p< 0.05 compared to GK). 
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non-diabetic rats treated with ASA. These results suggest enhanced utilization of 
glucose by peripheral tissues after ASA treatment in the GK rats. 
Figure 8: Effect of aspirin treatment on glucose tolerance. 
 
 
 
 
 
 
3.4 Effect of aspirin on serum biochemistry 
No significant alterations in the level of total serum proteins; uric acid, ALT, 
AST, LDH and CK (Figure 9A-F) was observed after ASA treatment. This suggests 
that the ASA treatment had no significant toxicity in the tissues. However, a 
significant decrease in triglyceride level was observed in GK rats, with no 
appreciable effect after ASA treatment (Figure 10C). This may suggest increased 
uptake and utilization of lipids as an initial compensatory mechanism for the lack of 
Glucose tolerance test in control Wistar (C) and GK rats treated with/without 
ASA (n=5). After an overnight fast, animals were injected with glucose (2g 
glucose/kg body weight) intraperitoneally. Blood samples were collected from the 
tail vein at time 0 (prior to the glucose load), 60 and 120 minutes after the glucose 
challenge and glucose levels tested as described in the Materials and Methods. 
S.E.M. from three independent experiments and  +Results are expressed as mean 
asterisks indicate significant difference. (* indicates p< 0.05 compared to control, 
** indicates p< 0.001 compared to control, ∆ indicates p< 0.05 compared to GK). 
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proper glucose utilization by peripheral tissues in GK rats. An increase in alkaline 
phosphatase and conjugated bilirubin was also observed in GK rats which were 
inhibited by ASA treatment (Figure 10D and 10E). This appears to be associated 
with mild cholestasis due to hypercholesterolemia seen in these rats.  
 
  
 
 
 
Tissue toxicity was measured in control Wistar (C) and GK rats. Serum separated from 
the blood of the rats was subjected to analysis for total protein (A), uric acid (B), 
Alanine aminotransferase (ALT) (C), Aspartate aminotransferase (AST) (D), Lactate 
dehydrogenase (LDH) (E) and Creatine kinase (CK)  (F) on the COBAS® INTEGRA 
400 plus auto-analyzer. Results are expressed as mean + S.E.M. from three 
independent experiments. 
Figure 9: Effect of aspirin treatment on tissue toxicity 
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We measured cholesterol, lipoprotein, triglyceride, alanine phosphatase (ALP) and direct 
bilirubin levels. Serum separated from the blood of the rats was subjected to analysis for 
cholesterol (A), total lipoproteins (B), Triglycerides (C), Alkaline phosphatase (ALP) (D) 
and conjugated bilirubin levels (E) on the COBAS® INTEGRA 400 plus auto-analyzer. 
Results are expressed as mean + S.E.M. from three independent experiments and asterisks 
indicate significant difference. (* indicates p< 0.05 compared to control, ** indicates p< 
0.001 compared to control, ∆ indicates p< 0.05 compared to GK). 
Figure 10: Effect of aspirin treatment on blood lipid profile. 
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3.5 Effects of aspirin on prostaglandin E2 level  
GK diabetic rats showed a significant (about 2-fold) increase in Prostaglandin 
E2 level indicating an increased inflammatory response (Figure 11). ASA treatment 
drastically reduced the level of PGE2 both in GK diabetic and control rats. 
Figure 11: Effect of aspirin treatment on Prostaglandin E2 levels. 
E2 was measured in control Wistar (C) and GK rats treated with/without ASA (n=5). 
Serum separated from the blood of the rats was assayed for prostaglandin E2 levels 
using an ELISA kit as described in the Materials and Methods. Results are expressed 
as mean + S.E.M. from three independent experiments and asterisks indicate 
significant difference. (** indicates p< 0.001 compared to control, ∆∆ indicates p< 
0.001 compared to GK).  
3.6 Effects of aspirin on reactive oxygen species and reactive nitrogen species 
A significant decrease in serum NO level was observed in GK diabetic rats 
(Figure 12A). ASA treatment significantly increased the level of NO. A slight 
increase in NO production was also observed in ASA treated control rats.  Serum 
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SOD level was significantly increased in ASA-treated GK diabetic rats but not in 
ASA-treated non-diabetic control rats (Figure 12B).  The increased SOD could be 
due to the increased peroxide radicals, which in turn, would be converted to H2O2 
and may be responsible for the increased insulin signaling.  This supports our finding 
of increased glucose tolerance after ASA treatment since ASA is known to play an 
important role in increasing insulin sensitivity. 
Figure 12: Effect of aspirin treatment on total nitric oxide and superoxide dismutase 
levels.  Total NO and SOD were measured in control Wistar (C) and GK rats treated 
with/without ASA (n=5). Serum separated from the blood of the rats was assayed for 
total NO level (A) and SOD (B) activity using the respective kits as described in the 
Materials and Methods. Results are expressed as mean + S.E.M. from three 
independent experiments and asterisks indicate significant difference. (* indicates p< 
0.05 compared to control, ** indicates p< 0.001 compared to control, ∆ indicates p< 
0.05 compared to GK, ∆∆ indicates p< 0.001 compared to GK). 
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3.7 Effect of aspirin on pancreatic insulin/glucagon secretory functions 
  Immunoreactivity of insulin- (β) and glucagon- (alpha) secreting cells in the 
pancreatic islets was checked using paraffin sections of pancreas (Figure 13). A 
significant decrease in size and number of the hormone secreting cells was observed 
in GK rats while ASA treatment improved the structural integrity and size of 
pancreatic islets. Quantitative analysis confirmed increased pancreatic islet size 
(Figure 8A) in ASA treated cells which correlated with their ability to regulate 
insulin secretion confirmed by the increased percentage of insulin secreting cells 
(Figure 14B) after ASA treatment. In addition, ASA treatment also enhanced the 
insulin/glucagon ratio which was significantly reduced in GK diabetic rats (Figure 
14C). 
Figure 13: Effect of aspirin treatment on β-cell insulin/glucagon level. 
Localization of insulin (green) and glucagon (red) in pancreatic islets was performed 
by a double-labeled immunofluorescence method and visualized with a Carl Zeiss 
fluorescent microscope as described in the Materials and Methods. Representative 
islets at X40 magnification selected from at least five sets of slides from each of the 
groups are shown. Bar represents 25 µm. 
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Figure 14: Effect of aspirin treatment on insulin/glucagon secretion 
To assess the effect of aspirin treatment, the size of the islets (A) was measured using 
Axiovision
®
 3.0 Image Analysis System (Zeiss, Gottingen, Germany) attached to the 
Carl Zeiss fluorescent microscope. Insulin- or glucagon-positive cells were counted 
in visible sections at X40 magnification. The number of insulin-immunoreactive cells 
was divided by the total number of cells to give the percentage of insulin secreting 
cells (B). The ratio of insulin positive to glucagon positive cells was also calculated 
(C). A total of 10 random islets were analyzed from a total of 5 slides in each group. 
Results are expressed as mean + S.E.M. and asterisks indicate significant difference. 
* indicates p< 0.05 compared to control, ** indicates p< 0.001 compared to control, 
∆ indicates p< 0.05 compared to GK, ∆∆ indicates p< 0.001 compared to GKا 
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3.8 Effect of aspirin on the expression of insulin 
Insulin expression in the serum and pancreas of GK and control rats was also 
studied by SDS-PAGE using a polyclonal antibody against insulin. An increased 
expression of serum insulin was observed in GK rats confirming the insulinemia in 
GK diabetic rats when compared to control non-diabetic rats (Figure 15A). ASA 
treatment reduced the amount of insulin in the serum supporting the results obtained 
by ELISA assay for serum insulin.  These results suggest alterations in glucose 
stimulated insulin synthesis after ASA treatment. Insulin expression decreased 
significantly in the pancreas of GK diabetic rats. However, an increased expression 
was observed after ASA treatment suggesting the recovery of β cells to produce 
insulin, but the levels were still comparatively higher than that seen in control rats. 
This could be because though the ASA treatment had improved glucose tolerance, 
the low dose of ASA for this time period was not enough to bring the glucose levels 
back to normal and thus bring the insulin levels also to control levels. 
The expression was measured in control Wistar (C) and GK rats treated with/without 
ASA (n=5). Pancreatic homogenates (50 µg) and serum samples (10 µg) were 
Figure 15: Effects of aspirin treatment on the expression of insulin in serum and pancreatic 
homogenates. 
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electrophoretically transferred by 15 % SDS-PAGE and Western blot analysis to 
visualize the expression of insulin (A). Β-actin was used as the loading control. The 
histograms in Fig. 9B shows densitometric analysis of the protein bands and are 
expressed as percentage protein compared to the control group. Asterisks indicate 
significant difference. (** indicates p< 0.001 compared to control, ∆ indicates p< 
0.05 compared to GK). The figures shown are representative of 3-4 independent 
analyses. 
 
3.9 Effects of aspirin on oxidative/nitrosative stress  
A significant increase in mitochondrial ROS production was observed in the 
pancreas (almost 80 %) and in the heart (about 50 %) of GK rats which was reduced 
almost to control levels after ASA treatment (Figure 16A). Control Wistar rats 
treated with ASA showed negligible ROS formation. Membrane-bound NADPH 
oxidase, however, was increased only in the heart and not the pancreas of GK rats 
(Figure 16B). This could suggest differential sources of ROS production the 
pancreas and heart in GK rats. 
 
66 
 
 
Figure 16: Effects of aspirin treatment on mitochondrial ROS and membrane-bound 
NOX levels.  ROS and NOX were measured in the pancreas and heart of control 
Wistar and GK rats. Mitochondrial ROS production (A) in the pancreas and heart of 
control Wistar and GK rats was measured using DCFDA as a probe. Total 
homogenates from the tissues of these animals were analyzed for membrane-bound 
NOX production using the lucigenin-enhanced chemiluminescence method as 
described in the Materials and Methods.   Asterisks indicate significant difference. * 
indicates p< 0.05 compared to control, ** indicates p< 0.001 compared to control, ∆ 
indicates p< 0.05 compared to GK, ∆∆ indicates p< 0.001 compared to GK.The 
figures shown are representative of 3-4 independent analyses. 
A significant increase in pancreatic SOD and decrease in heart SOD levels 
was observed (Figure 17). ASA treatment again brought back the values close to the 
control. No difference was observed in the control rats treated with ASA. This 
explains the increased insulin signaling by ASA treatment due to the low levels of 
NO/H2O2. 
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3.10 Effects of aspirin on lipid peroxidation  
Microsomal LPO was significantly increased (about 60-70 %) in both the 
pancreas and heart of GK rats (Figure 18). ASA treatment markedly reduced the 
levels in both, though it was still much above the control levels.  This could be due to 
the increased peroxide formation suggestive of increased oxidative stress in diabetic 
rat tissues. 
 
 SOD was measured in the pancreas and heart of control Wistar and GK rats.  
Tissue homogenate from control Wistar and GK rat pancreas and heart was 
analysed for SOD as described in the Materials and Methods. Results are 
expressed as mean + S.E.M. from three independent experiments and asterisks 
indicate significant difference * indicates p< 0.05 compared to control and ∆ 
indicates p< 0.05 compared to GK, ∆∆ indicates p< 0.001 compared to GK. 
Figure 17: Effects of ASA treatment on superoxide dismutase levels. 
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Figure18: Effects of aspirin treatment on lipid peroxidation in the pancreas and heart 
 
 
 
 
 
 
 
3.11 Effects of aspirin on GSH-dependent redox metabolism 
A significant increase (about 30 %) and non-significant in the cytosolic 
protein-free GSH were observed in the pancreas and heart respectively (Figure 19A). 
There was no effect on the mitochondrial GSH in the pancreas though the heart 
showed a slight decline in the GK animals (Figure 19B). 
GSH-CDNB conjugating activity by GST enzyme in the cytosolic fraction 
showed very mild alterations both in the pancreas and heart (Figure 19C). However, 
the mitochondrial fraction of the pancreas showed a significant decrease in GST 
activity in the GK rats and ASA treatment increased the activity (Figure 19D). This 
 LPO was measured in control Wistar and GK rats.  NADPH-dependent LPO was 
measured in the pancreas and heart of control Wistar and GK rats using the LPO kit 
from Oxis Int. as described in the Materials and Methods.  Asterisks indicate significant 
difference. * indicates p< 0.05 compared to control. ** indicates p< 0.001 compared to 
control, ∆∆ indicates p< 0.001 compared to GK. The figures shown are representative  
of  3-4 independent analyses. 
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could be due to the increased conjugation of the GST enzyme due to the increased 
mitochondrial ROS production in the pancreas. Comparatively, only a mild increase 
in the activity was observed in the heart tissue, though ASA treatment seemed to 
increase the activity significantly. These results suggest the differential response in 
maintaining the GSH pool and its conjugating activity in the pancreas and heart of 
diabetic GK animals. 
Increased GSH-Px activity in the pancreas was observed both in the cytosolic 
as well as the mitochondrial fractions of GK rats as well as after treatment with ASA 
(Figure 19E, F).  The heart, however, showed no significant alterations in the cytosol 
whereas mild alterations were observed in the mitochondria. This may suggest that 
the pancreas is under more oxidative stress conditions when compared to the heart 
and that there seems to be more protection in the heart from increased peroxide 
formation. 
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GSH-Px was measured in the pancreas and heart of control Wistar and GK rats 
treated with ASA   GSH concentration in the pancreas and heart of control Wistar 
and GK rats was measured in the cytosol (A) and mitochondria (B) by the enzymatic 
recycling method of Griffith as described in the Materials and Methods. GST 
activity, using CDNB as substrate, in the pancreas and heart of control Wistar and 
GK rats was measured in the cytosol (C) and mitochondria (D) as described in the 
Materials and Methods. GSH-Px activity in the pancreas and heart of control Wistar 
and GK rats was measured in the cytosol (E) and mitochondria (F) using cumene 
hydroperoxide as substrate as described in the Materials and Methods. Asterisks 
indicate significant difference * indicates p< 0.05 compared to control, ** indicates 
p< 0.001 compared to control, ∆ indicates p< 0.05 compared to GK, ∆∆ indicates p< 
0.001 compared to GK. The figures shown are representative of 3-4 independent 
analyses. 
Figure 19: Glutathione levels and metabolism. 
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3.12 Effects of aspirin on CYP activities 
A significant increase (60 %) in CYP 2E1 activity in the pancreas and a 35 % 
increase in the heart were observed (Figure 20A).  This increase in activity could be 
due to increased oxidative stress. ASA treatment brought the activity to control level 
in both the tissues. Similarly, CYP 3A4 activity was also significantly increased in 
both the pancreas and heart (Figure 20B). However, ASA treatment could not bring 
the activity back to control levels in both the tissues. In fact, the activity increased 
further after ASA treatment in the heart tissue. This could be because of differential 
isoenzyme expression in the heart and maybe because CYP 3A4 is involved in ASA 
metabolism. 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: CYP 450 levels. 
CYP 450 was measured in the pancreas and heart of control Wistar and GK rats 
treated with aspirin.  CYP 2E1 (A) and CYP 3A4 (B) activities in the liver and 
kidney microsomal fractions were measured using standard substrates as described in 
the Materials and Methods. Results are expressed as mean + S.E.M. from three 
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independent experiments and asterisks indicate significant difference. * indicates p< 
0.05 compared to control, ** indicates p< 0.001 compared to control, ∆ indicates p< 
0.05 compared to GK, ∆∆ indicates p< 0.001 compared to GK.  The figures shown 
are representative of 3-4 independent analyses. 
3.13 Effects of aspirin on mitochondrial bioenergetics 
Respiratory Complex I activity was markedly reduced in both pancreas and 
heart mitochondria of GK rats (Figure 21A). Treatment with ASA increased the 
activity to almost control levels. Similarly, Complex II/III activity also was 
significantly reduced in both the tissues of GK rats (Figure 21B). Treatment with 
ASA again significantly increased the activity to control levels in both the pancreas 
as well as the heart. However, not significant alteration in respiratory Complex IV 
activity was found in either pancreas or heart (Figure 21C). On the other hand, 
mitochondrial ATP levels were markedly reduced in the pancreas and heart of GK 
animals (Figure 21D) though ASA treatment brought the levels to be similar to 
control rats. This shows that ASA treatment has beneficial effects by increasing 
energy utilization and ATP production.  
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Measurement was done in the pancreas and heart of control Wistar and GK rats.  
 
Figure 21: Effect of aspirin on the activities of mitochondrial complexes and ATP levels. 
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Mitochondrial respiratory enzyme Complexes I,II/III and IV (A,B,C) activities were 
measured in freshly prepared mitochondrial fractions  from the pancreas and heart of 
control Wistar and GK rats using enzyme specific  substrates as described in the 
Materials and Methods. The ATP content (D) in the rat tissues was determined using 
ATP Bioluminescent cell assay kit (Sigma, St Louis, MO). Results are expressed as 
mean + S.E.M. from three independent experiments and asterisks indicate significant 
difference. * indicates p< 0.05 compared to control, ** indicates p< 0.001 compared 
to control, ∆ indicates p< 0.05 compared to GK, ∆∆ indicates p< 0.001 compared to 
GK). 
 
3.14 Effects of aspirin on energy metabolizing cytosolic and mitochondrial 
enzymes 
Glucose phosphorylation by hexokinase enzyme was significantly increased 
in both pancreas and heart of GK rats (Figure 22A). ASA treatment further increased 
the activity. On the other hand, activity of the mitochondrial enzyme, GDH was 
significantly reduced in both the tissues of GK rats (Figure 22B). However, ASA 
treatment improved the levels significantly. No change in activity was observed in 
the control rats treated with ASA. These results imply improved energy utilization 
and insulin responses in the pancreas and heart of GK diabetic animals after ASA 
treatment. 
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  Figure 22: Effect of aspirin on hexokinase and glutamate dehydrogenase activities 
 
 
 
 
 
 
3.15 Effects of aspirin on the expression of key redox-sensitive marker proteins 
The increase in tyrosine phosphorylation of downstream insulin signaling 
kinases promotes insulin signaling via the IRS1/2 signaling pathway. Increased 
phosphorylation of Akt protein was observed after ASA treatment (Figure 23A) in 
Measurement was done in the pancreas and heart of control Wistar and GK rats. 
Hexokinase (A)  and  glutamate dehydrogenase (B)  were measured in the pancreas 
and heart of control Wistar and GK rats using the respective kit protocols as 
described in the Materials and Methods. Results are expressed as mean + S.E.M. 
from three independent experiments and asterisks indicate significant difference. * 
indicates p< 0.05 compared to control, ** indicates p< 0.001 compared to control, 
∆ indicates p< 0.05 compared to GK, ∆∆ indicates p< 0.001 compared to GK. 
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the pancreas of control Wistar rats as well as GK rats. Increased phosphorylation was 
also observed in the heart of control rats after ASA treatment. Significant increase in 
phosphorylation of JNK protein was also observed in the pancreas and heart of both 
GK and control Wistar rats (Figure 23B). Increased activation of PPAR-γ was also 
observed after ASA treatment in both pancreas and heart tissues of GK rats (Figure 
23C), though the increase was more significant in the heart tissues of GK rats. This 
suggests an improved fatty acid metabolism after ASA treatment, thus regulating 
lipid metabolism. This may also explain the reduced level of triglycerides in GK rats.  
Increased carbonylation of proteins by 4-HNE conjugation was observed in 
the pancreas of GK rats (Figure 23D). ASA treatment markedly decreased the level 
of conjugation. The heart tissue however did not show any difference in protein 
carbonylation, again suggesting increased oxidative stress in the pancreas. The heart 
appears to be exhibiting extra level of redox-protection from the oxidative stress. 
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Figure 23: Expression of specific marker proteins. 
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Measurement was done in the pancreas and heart of control Wistar and GK rats 
treated with aspirin.   Homogenates (50 µg protein) from the pancreas and heart of 
control Wistar and GK rats were subjected to 12 % SDS-PAGE and Western blot 
analyses to visualize immunoreactivity of specific marker proteins: Akt, p-Akt 
(A),JNK, p-JNK (B) and PPAR-γ and HNE (C). Beta-actin was used as loading 
control. Histograms represent the ratio of the signals of phosphorylated to 
unphosphorylated proteins, in (A) and (B) whereas it represents the ratio of the 
protein to that of actin in (C) and are expressed as fold increase using the ratio of 
control proteins as 1.0. The figures shown are representative of 2-3 independent 
analyses. Molecular weights shown are in kDa.  
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Chapter 4: Discussion 
DM is a progressive metabolic disorder attributed to rapid economic 
development and changes in life style that have led to reduced physical activity, 
increased intake of refined high calorie diet and a rise in obesity (1, 3).  The 
increasing incidence of diabetes, particularly T2DM, worldwide, has cost billions of 
dollars in the treatment and management of this disease.  T2DM is a multifactorial 
metabolic syndrome associated with progressive impaired insulin secretion, insulin 
response and resistance and characterized by compromised energy metabolism, 
hyperglycemia, hyperlipidemia, and cardiovascular abnormalities. However, the 
precise molecular mechanisms of disease progression and complications are still 
unclear. The GK rat is a spontaneous non-obese animal experimental model of 
T2DM. This strain was developed by selective breeding of glucose intolerant Wistar 
rats over many generations. The GK rats exhibit decreased β-cell numbers and 
function which is accompanied by mild hyperglycemia, impaired glucose-induced 
insulin secretion, marked glucose intolerance, peripheral insulin resistance and 
chronic inflammation (101-102, 142).  Despite the mild hyperglycemia several 
manifestations of diabetes complications have been demonstrated in this model (143-
145). 
Growing evidence has linked T2DM with inflammation. Thus, the GK rat 
represents a good animal model for studying human T2DM pathophysiology and the 
effects of therapeutic options such as the use of ASA or other NSAIDs.  It is possible 
that existing low-grade systemic inflammation can be suppressed by experimental 
strategies aimed at blocking the production or action of proinflammatory signaling 
pathways, thereby treating T2DM. There are several studies on the glycemic effects 
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of salicylates and ASA (acetylated salicylic acid) in the literature, but the mechanism 
of their antidiabetic effects is still unclear (106, 146).  Recently, sodium salicylate 
and aspirin have been shown to inhibit activation of the transcription factor NF-κB 
(107) by preventing degradation of IKK-β, which regulates the inflammatory 
responses, and might therefore ameliorate insulin resistance and improve glucose 
tolerance in at least some patients with T2DM. However, the exact mechanism and 
effects of ASA on treatment of T2DM are still not fully understood.  
 
Salicylates have also been shown to enhance metabolic rate and energy 
expenditure in GK rats (108).  Recent studies on experimental rodent models of 
diabetes and clinical trials have demonstrated beneficial and deleterious effects of 
ASA on diabetes-associated complications and insulin sensitivity depending upon the 
dose of aspirin and experimental model used (109-112, 147). 
Our recent studies in diabetic rats have demonstrated that diabetes-associated 
hyperglycemia caused tissue-specific increase in oxidative stress and mitochondrial 
dysfunction (114,116,117,148). 
 
Low grade systemic inflammation is considered an integral part of T2DM and 
plays an important role in glycemic control (149).The GK rats are a useful model to 
evaluate the mechanism of effects of ASA on disease progression. The aim of the 
present study was to evaluate the potential role of aspirin and the biochemical 
mechanism involved in improving glucose tolerance and insulin sensitivity in type 2 
mildly diabetic GK rats. The objective was to investigate the effect of ASA on 1) 
pancreatic β-cell structural integrity; 2) insulin secretion and insulinemia;3) insulin 
signaling; 4) energy metabolism and mitochondrial function;5) oxidative stress and 
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glutathione-dependent redox metabolism;6) drug metabolizing and detoxification 
enzyme systems. We have demonstrated that low dose ASA (100 mg/Kg body wt. / 
I.P.) treatment for 5 weeks reduced hyperglycemia and hyperinsulinemia with 
improved glucose tolerance (utilization) by peripheral tissues without causing any 
appreciable toxicity in target tissues. Improved insulin secretory function in these 
rats was also observed. Our results have also suggested that insulin signaling was 
improved causing an increase in energy metabolism after ASA treatment. We also 
demonstrated an improvement in the drug metabolizing abilities in the pancreas and 
heart of ASA-treated GK rats as suggested by the alterations in the cytochrome P450 
and GSH-conjugating drug metabolizing enzymes. However, the ASA treatment 
caused no significant alterations in the activities of ALT, AST, total proteins, uric 
acid, LDH or CK.   A mild liver toxicity was, however, observed in rats treated with 
ASA. This may be due to increased cholestasis. This effect is mostly idiosyncratic 
and is independent of the dose administered (150). 
 
Insulinemia, hypercholesterolemia and hyperlipoproteinemia, in GK rats may 
have caused insulin resistance resulting in hyperglycemia (149,151).  Our results 
have shown a marked increase in total cholesterol level in GK rats which was 
significantly reduced after ASA treatment (Figure 9A).  However, the cholesterol 
level remains higher in GK rats treated with ASA than that seen in the control Wistar 
rats. Although the individual lipoproteins were varying both in the control and GK 
diabetic rats, ASA treatment caused a significant reduction in the total lipoproteins 
(Figure 9B).  Recent study by Wang et al. (151) also demonstrated that salacylate 
treatment, in addition to a decrease in blood insulin and blood glucose levels, reduces 
the levels of total cholesterol and lipoproteins. Serum triglyceride level was however 
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lower in GK rats compared to the control rats and ASA treatment had no significant 
effect on the level of TG in GK rats. This may suggest increased uptake of lipids in 
GK rats by peripheral tissues as a compensatory mechanism for obtaining energy 
from fatty acid instead of glucose. ASA has been shown to inhibit lipogenesis in the 
tissues and activate lipases to generate energy metabolizing fatty acids as a 
compensatory mechanism. There are reports suggesting that ASA acts in synergy 
with metformin in improving lipid metabolism and insulin sensitivity (152).  ASA 
treatment improves insulin sensitivity by increasing the whole body fatty acid 
oxidation and by protecting the IRS from serine phosphorylation which inhibits 
downstream insulin signaling (153). This effect of ASA is associated with its anti-
inflammatory action as well as direct activation of AMP-activated protein kinases 
(154, 155). 
 
Our results have also indicated a marked increase in serum PGE2 level in GK 
rats which may have contributed to increased inflammation.  It is possible that 
treatment with anti-inflammatory agent may result in reducing the proinflammatory 
signals and responses in type 2 diabetes.  We have shown that ASA treatment 
markedly reduced the production of PGE2 in control and GK rats.  GK rats, on the 
other hand showed markedly increased production of PGE2 (Figure 11).  Increased 
PGE2 and E-prostanoid receptors (EP2/3) negatively regulate insulin secretion and 
signaling and has been linked to the pathophysiology of T2DM (156). Therefore, 
inhibition of PGE2 by ASA may play a significant role in PGE2/ EP3 mediated 
modulation in β-cell function and insulin signaling.  
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There are reports showing that ASA increases NO production in cells and 
tissues (155) and that NO plays an important role in increasing insulin sensitivity by 
reducing the sensitivity of cells towards prooxidants (155-157). 
NO is a freely diffusible reactive nitrogen species (RNS). Local production of 
superoxide, such as within β-cells, protects the cells by scavenging NO.  Low levels 
of H2O2 have also been shown to induce NO production and insulin sensitivity.  ASA 
has been reported to protect cells from oxidative damages by stimulation of 
endothelial NO production (155). There are reports that NO synthesis is reduced in 
T2DMM and hypertension and that insulin regulates NO production (156, 157). We 
observed that serum NO level was low in GK rats and ASA treatment increased NO 
production (Figure 12A), which may have stimulated glucose tolerance and increased 
insulin response. The regulation of NO metabolism in T2DM plays an important role 
in insulin dependent Akt signaling and therefor disturbances of NO generation are 
detrimental in insulin resistance (156).  Our results show that ASA treatment appears 
to have beneficial effect on the NO production in GK rat tissues. 
 
We observed that ASA treatment increased serum SOD activity (Figure 17).  
SOD converts toxic superoxides to H2O2 and thus may help in H2O2-dependent 
insulin signaling and increased glucose transport in target cells. Insulin signaling is 
reported to be positively and negatively affected by ROS production.  At a low 
physiological level, H2O2 is involved in enhancing insulin signaling by activating 
insulin receptor-tyrosine kinase activity and engaging the IRS-1/PI3k/AKT-
dependent downward signaling to increase basal glucose transport activity (158).  At 
lower concentrations, H2O2 has been reported to mimic insulin signaling even in the 
absence or low levels of insulin and inhibits PTP1B activity to prolong insulin 
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receptor tyrosine kinase activity. In contrast, in the presence of insulin, H2O2 inhibits 
insulin signaling by activating deleterious serine/threonine kinases developing 
insulin resistance (159, 160). Persistent hyperglycemia and insulinemia, systemic and 
islet inflammation and increased ROS are all involved in developing insulin 
resistance and β cells structural and functional defects in T2DM (161, 163).  Clinical 
and experimental trials have validated the beneficial effects of anti-inflammatory 
therapies including ASA treatment (149, 151, 162, 164).  Emerging results suggest 
that both β cell mass and abnormal secretory functions are implicated in T2DM (165, 
166). As shown in our immunofluorescence study (Figure 13), ASA treatment has 
improved both the structural and functional properties of β islets. This may be 
associated with the anti-inflammatory property of ASA which helps in regenerating 
functional β cells, glucose stimulated insulin secretion, insulin sensitivity, glucose 
transport and energy utilization in T2DM. 
 
In diabetes, hyperglycemia and hyperlipidemia are associated with increased 
ROS production and oxidative stress (115, 167, 168, 169, 170).  Excessive 
superoxide production, however, either by NOX or mitochondrial respiration may 
result in excessive formation of peroxynitrite a highly reactive nitrogen species, 
which may accelerate the deleterious metabolic complications in diabetes. Using 
both type 1 and type 2 diabetes rat models we have shown the excessive production 
of ROS, increased oxidative stress associated mitochondrial and metabolic stress in 
the tissues (114- 117, 148).  Our present study on GK diabetic rats has also exhibited 
an increased oxidative stress related metabolic changes and mitochondrial 
dysfunction in the pancreas and heart. ASA treatment however had some beneficial 
effects. As shown by SDS-PAGE analysis, the increased carbonylation by 4-HNE-
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conjugation of oxidized proteins was observed in GK rat tissues. ASA treatment 
decreased the oxidative 4-HNE-conjugation of proteins. GK rats pancreatic β-cells 
have been shown to be oxidatively stressed and have high-HNE-modified proteins 
(161). ASA appears to be protecting the mitochondrial proteins from oxidative 
carbonylation thus preventing mitochondrial dysfunction which is linked to develop 
insulin resistance in the tissues (171). 
 
Our SDS-PAGE analysis (Figure 23) also revealed that ASA treatment 
increased AKT and JNK phosphorylation which promotes insulin signaling via 
activation of IRS1/2 and insulin-dependent downstream signaling. ASA treatment 
has also been shown to inhibit serine phosphorylation of IRS as seen in inflammatory 
responses, thereby stimulating the tyrosine phosphorylation of IRS through AKT 
pathways resulting in increased insulin sensitivity. The effect is associated with the 
anti-inflammatory action of ASA (153, 154, 172, 173).  Activation of PPAR-ϒ in the 
pancreas and heart tissues after ASA treatment also suggests an improved fatty acid 
metabolism in GK rats treated with ASA. PPAR-ϒ family of nuclear receptors play 
an important role in the regulation of lipid metabolism by stimulating the genes 
involved in the lipid uptake and adipocytes differentiation. PPAR-ϒ agonists of the 
thiazolidine (TZD) family are being extensively used for the treatment of T2DM due 
to their insulin sensitizing properties. Increased expression of this protein in the 
tissues of GK rats after ASA treatment suggests another mechanism of improving 
insulin responses by ASA treatment (174).  Another mechanism proposed by TZD is 
that it inhibits mitochondrial respiratory complexes in mitochondria, like metformin, 
and pyruvate carrier resulting in the activation of AMPK which facilitates 
mitochondrial biogenesis and hence insulin responsive increase in energy utilization 
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(175, 176). Our results on GK rats also support these observations and add a 
mechanistic explanation of ASA action in improving T2DM. 
 
Mitochondrial oxygen /energy metabolism to generate ATP via oxidative 
phosphorylation is also accompanied by ROS production. Mitochondria generate 
moderate levels of ROS during normal oxygen metabolism in oxidative 
phosphorylation during the metabolism of glucose and fatty acids. The low level of 
ROS enhances insulin sensitivity upon redox regulation of insulin receptor (tyrosine 
kinase) and substrates (IRS family). However, chronic exposure to high levels of 
ROS produced in T2DM could alter the mitochondrial function and thereby cause 
insulin resistance. Our results on GK rats have shown a compromised mitochondrial 
respiratory function with altered enzyme activities of inner membrane respiratory 
complexes (Figure 21).  These results confirm our previous observations on STZ-
induced diabetes or on Zucker type 2 fatty rat tissues (114-117, 148).  ASA treatment 
seems to have beneficial effects by altering the mitochondrial functions in favor of 
energy metabolism and improved insulin signaling as observed by increase glucose 
phosphorylation by hexokinase and by increasing the activity of glutamate 
dehydrogenase (GDH) which generates alpha-ketoglutarate, an intermediate of 
tricarboxylic acid cycle. Activation of GDH has been associated with increased 
insulin secretion and energy metabolism (177, 178). 
We have also observed that ASA treatment not only affected the 
mitochondrial function and oxidative stress but also involved in regulating GSH-
dependent antioxidant homeostasis as well as CYP-dependent metabolism in the 
pancreas and heart of GK rats. The CYP 2E1 activity was increased in GK diabetic 
88 
 
rats suggesting the ROS mediated oxidative and metabolic stress (Figure 14A) (114-
117, 148).  ASA treatment resulted in the reduction of CYP activity. Similarly, CYP 
3A4 activity was also affected by ASA treatment suggesting the adaptation of 
metabolic stress in GK rats (Figure 20B).  This may also suggest a differential 
isoenzyme specific metabolism of ASA in the pancreas and heart. GSH-antioxidant 
pool as well as GST enzyme which conjugates endogenous oxidants such as HNE 
and other lipid peroxides was also altered after ASA treatment. These results have 
confirmed our previous observation (114-117, 148, 179) of altered drug metabolism 
in diabetes.  ASA appears to have some adaptation in improving the drug 
metabolizing abilities of the tissues. 
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Chapter 5: Conclusion 
 
With more than 350 million estimated global cases, diabetes is a pandemic 
disease with increasing morbidity and mortality. In the absence of an appropriate 
prevention and poor management, the current predictions for diabetes prevalence 
could double by 2035. Approximately 90 % of diabetics have T2DM with multiple 
etiological bases. While intervention by life style management and dietary control is 
an acceptable strategy to control energy metabolism, it is difficult to adhere to 
lifestyle changes for a long period of time. Moreover, the efficacy of current anti-
diabetic drugs is limited with unwanted side effects. Consequently there is a need 
and demand for the development of safer and more effective drugs in type 2 diabetes. 
Therefore, it is important to understand the mechanisms involved in the etiology and 
pathophysiology and progression of insulin resistant T2DM and to identify the key 
molecular targets for anti-diabetic therapeutics. Chronic hyperinsulinemia, 
glucotoxicity and lipotoxicity have been identified as the major causes of insulin 
resistance and diabetes-associated complications.  The onset of diabetes may start 
with pancreatic β-cell structural and functional defects, insulin secretion and glucose 
stimulated insulin release, insulin circulation and insulin signaling.  The progression 
of the disease due to excessive availability of glucose and fatty acids include insulin-
insensitivity in target tissues.  Additionally, mitochondrial dysfunction with reduced 
fatty acid and energy metabolism may result in increased ROS production and 
oxidative stress with compromised redox-homeostasis resulting in the deterioration 
of the structural and functional integrity of tissues. The most common features are 
progressive metabolic syndrome with diabetic-induced retinopathy, neuropathy and 
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nephropathy. Mitochondrial dysfunction is considered to be an important cause of 
insulin resistance with compromised energy utilization. 
ASA has been around for a long time for the treatment of cardiovascular 
diseases. In 2007, the ADA and AHA jointly recommended that ASA (75 to 162 
mg/day), to be used as a primary preventive drug in T2DM patients with increased 
cardiovascular risks (180).  However, there are conflicting reports and disagreement 
regarding the use of ASA for primary prevention in diabetes (181). Moreover, 
measuring the response to ASA is often difficult as some patients may show ASA 
resistance. Furthermore, there are other potential factors which may affect ASA 
efficacy in patients which include: ASA dose, disease severity, genetics, obesity and 
inflammation, smoking and complications of the disease and interactions with other 
drugs. 
The objective of the present study was to further investigate the mechanism 
of ASA action on young GK diabetic-insulin resistant rats using an accepted 
effective dose based on the literature search and injecting the drug intraperitoneally 
(I.P.) to avoid gastric toxicity caused by ASA. Our hypothesis was; 1) to elucidate 
the mechanism of ASA action on pancreatic β-cell structure and insulin secretion; 2) 
study the effect of ASA on insulinemia and hyperglycemia/dyslipidemia; 3) to study 
the effect of ASA on glucose tolerance;4) to study the effect of ASA on insulin 
signaling; 5) to study the effect of ASA on energy metabolism; 6) to study the effect 
of ASA on mitochondrial functions and oxidative stress and 7) to study the effect of 
ASA on drug metabolism. Our results suggest that ASA has improved β-cells 
integrity and insulin secretory function. We have also shown that ASA treatment to 
GK rats has improved glucose tolerance, insulin signaling based on Akt/JNK 
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phosphorylations and energy metabolism with improved glucose and lipid 
metabolism in the pancreas and heart. ASA treatment also altered oxidative stress, 
mitochondrial function and redox homeostasis which may have consequences in 
developing insulin-sensitivity in diabetes.  
Further studies are needed to study the mechanism of ASA action using 
different doses and routes of administration along with clinically approved anti-
diabetic drugs.  Also, we need to elucidate the effect of ASA on energy metabolism, 
mitochondrial function, oxidative stress, insulin signaling response in different 
tissues from young and chronic diabetic rats. Identification of molecular targets for 
downstream insulin signaling affecting the energy (glucose and fatty acids) 
metabolism in GK rats will highlight the efficacy of ASA alone or in combination 
with clinically approved anti-diabetic drugs in type 2 diabetic animal models. Our 
study might be helpful in designing strategies for the therapeutic management of 
insulin-resistant T2DM. 
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